

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/11, C07H 21/04, A61K 31/70	A2	(11) International Publication Number: WO 98/33904 (43) International Publication Date: 6 August 1998 (06.08.98)
(21) International Application Number: PCT/EP98/00497 (22) International Filing Date: 30 January 1998 (30.01.98) (30) Priority Data: 97101531.8 31 January 1997 (31.01.97) EP (34) Countries for which the regional or international application was filed: DE et al. (71) Applicant (for all designated States except US): BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK MBH [DE/DE]; Gerhard-Gerdes-Strasse 19, D-37079 Göttingen (DE). (72) Inventors; and (75) Inventors/Applicants (for US only): SCHLINGENSIEPEN, Karl-Hermann [DE/DE]; Pappelweg 3, D-37085 Göttingen (DE). BRYSCH, Wolfgang [DE/DE]; Calsowstrasse 56, D-37085 Göttingen (DE). (74) Agents: MEYERS, Hans-Wilhelm et al.; P.O. Box 10 22 41, D-50462 Cologne (DE).	(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DE, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD		
(57) Abstract <p>A method for the preparation of an antisense oligonucleotide or derivative thereof comprising the steps of: selecting a target nucleic acid, if necessary elucidating its sequence; generating the antisense oligonucleotide with the proviso that: the oligonucleotide comprises at least 8 residues; the oligonucleotide comprises at maximum twelve elements, which are capable of forming three hydrogen bonds each to cytosine bases; the oligonucleotide does not contain four or more consecutive elements, capable of forming three hydrogen bonds each with four consecutive cytosine bases (CCCC) within the target molecule or alternatively four or more consecutive elements of GGGG; the oligonucleotide does also not contain 2 or more series of three consecutive elements, capable of forming three hydrogen bonds each with three consecutive cytosine bases (CCC) within the target molecule, or alternatively 2 or more series of three consecutive elements of GGG; and the ratio between residues forming two hydrogen bonds per residue (2H-bond-R) with the target molecule and those residues forming three hydrogen bonds per residue (3H-bond-R) with the target molecule, is ruled by the following specifications: $3H\text{-bond-R}/3H\text{-bond-R} + 2H\text{-bond-R} \geq 0.29$; and synthesizing the oligonucleotide thus generated in a per se known manner.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Switzerland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

An antisense oligonucleotide preparation method

The present invention is related to a method for the preparation of antisense oligonucleotides and to an oligonucleotide or functional or structural analogs or effective derivatives thereof, forming hydrogen bonds with deoxyribonucleic acids (DNA) and/or ribonucleic acids (RNA) or derivatives thereof including, but not limited to the formation of hydrogen bonds with the bases adenine (A), cytosine (C), guanine (G), uracil (U) or thymidine (T) contained in such molecules or forming hydrogen bonds with residues of a particular protein, such a molecule being capable of altering the expression structure or function, of a gene, an RNA molecule or a protein or altering the level of activity of a gene, an RNA molecule or a protein. Furthermore, the present invention is related to such nucleic acid or functional or structural analogs or effective derivatives thereof, coupled or mixed with folic acid, hormones, steroid hormones such as oestrogen, progesterone, corticosteroids, mineralocorticoids, androgens, peptides, proteoglycans, phospholipids, glycolipids and derivatives therefrom.

Furthermore, the invention is related to the use of said nucleic acids or functional or structural analogs or effec-

- 2 -

tive derivatives thereof, for analyzing the functional properties of a particular gene, RNA, or protein by altering its activity, structure, function or altering its expression levels.

Furthermore, the invention is related to antisense nucleic acids, capable of modulating the expression or functional activity of proteins which regulate cell growth leading to augmentation, inhibition or modulation of cell growth or cell proliferation and/or the expansion of primary cells or stem cells, e.g. in culture or in the living organism.

Furthermore, the invention is related to a pharmaceutical composition comprising said nucleic acids or functional or structural analogs or effective derivatives thereof, hybridizing with an area of the messenger RNA (mRNA) or the DNA of a target gene or binding to a particular protein as well as the use of said nucleic acids, structural analogs and derivatives thereof for the manufacturing of a pharmaceutical composition for the treatment of diseases where the alteration of the structure function, activity or expression of a particular target gene, a particular target RNA or a particular target proteins activity leads to a therapeutic benefit related to the effect of the nucleic acid or derivative thereof.

Modulation of the expression of genes, RNA molecules or proteins or of their activity levels with nucleic acids or functional or structural analogs or effective derivatives thereof is a powerful means to study the function of the respective molecules. For example modulation, e. g. knockdown or increase of the expression of a particular protein can lead to the identification of its physiological as well as its pathophysiological roles in cultured cells as well as in living organisms in vivo.

- 3 -

Furthermore, the aberrant expression or overexpression of genes, RNA molecules or proteins, the expression of foreign DNA, RNA or proteins e. g. derived from infectious organisms or the expression of mutated DNA, RNA and proteins is found in a variety of diseases. Downregulation of the expression or the activity of such DNA, RNA and/or proteins can lead to an inhibition of or to the reversal of pathological processes in which the expression of a particular DNA, RNA and/or protein plays a role. However, nucleic acids or derivatives thereof used for downregulation of DNA, RNA and/or protein expression are often ineffective and/or toxic to the cells or the organisms treated with such molecules.

An object of the present invention is to provide a method for designing and preparation of oligonucleotides or derivatives thereof which avoid the drawbacks of prior art, and give a reliable method for preparation of oligonucleotides having increased effectivity and/or reduced toxicity and/or reduced non-selective effects.

The object is attained by a method having the features of claims 1. Preferred embodiments of the method of the invention are those according to claims 2 to 7.

The method of the invention comprises the steps

- of selecting a target nucleic acid, if necessary elucidating its sequence
- generating the antisense oligonucleotide with the proviso that
 - the oligonucleotide comprises at least 8 residues,
 - the oligonucleotide comprises at maximum twelve elements, which are capable of forming three hydrogen bonds each to cytosine bases,

- 4 -

- the oligonucleotide does not contain four or more consecutive elements, capable of forming three hydrogen bonds each with four consecutive cytosine bases (CCCC) within the target molecule or alternatively four or more consecutive elements of GGGG,
- the oligonucleotide does also not contain 2 or more series of three consecutive elements, capable of forming three hydrogen bonds each with three consecutive cytosine bases (CCC) within the target molecule, or alternatively 2 or more series of three consecutive elements of GGG, and
- the ratio between residues forming two hydrogen bonds per residue (2H-bond-R) with the target molecule and those residues forming three hydrogen bonds per residue (3H-bond-R) with the target molecule, is ruled by the following specifications:

$$3H\text{-bond-R}$$

$$\geq 0.29$$

$$3H\text{-bond-R} + 2H\text{-bond-R}$$

- and synthesizing the oligonucleotide thus generated in a per se known manner.

The generated antisense oligonucleotide comprises at least 8 residues in order to have sufficient interaction with the target molecule and has preferably up to 30, more preferably up to 24 or most preferred up to 18 residues. Shorter chain length are preferred over longer ones to increase specificity and/or reduce non-specific effects.

The oligonucleotide comprises at maximum 12 elements which are capable of forming 3 hydrogen bonds each to cytosine bases. In case of generating an oligonucleotide an element is represented by a residue, thus a nucleotide of the oligo-

- 5 -

nucleotide. In cases of generating a derivative an element is considered as a part of the molecule capable of forming hydrogen bonds. It is preferred that the oligonucleotide comprises at maximum 10 and more preferred at maximum 8 elements which are capable of forming 3 hydrogen bonds each to cytosine bases.

The generated antisense oligonucleotide preferably does not contain 4 or more consecutive guanine bases and does also not contain 2 or more series of 3 consecutive guanine bases.

Preferably, the ratio between residues forming 2 hydrogen bonds per residue (2H-bond-R) with their target molecule and those residues forming 3 hydrogen bonds per residue (3H-bond-R) :

$$\frac{3H-bond-R}{-----}$$
$$3H-bond-R + 2H-bond-R$$

is in the range of greater than 0.33 and smaller than 0.86, more preferably smaller than 0.79 and still more preferred smaller than 0.72.

In one embodiment the oligonucleotides generated by the method of the invention are modified for higher nuclease resistance than naturally occurring nucleotides. Methods for synthesizing oligonucleotides and derivatives thereof are known in the art, see for example "Oligonucleotides and Analogues", F. Eckstein (Ed.), 1991, IRL Press Oxford or "Protocols for Oligonucleotides and Analogs, Synthesis and Properties", Sudhir Agrawal (Ed.), 1993, Humana Press, Totowa, New Jersey.

Oligonucleotides of the invention may also contain RNA and DNA residues within their chains.

- 6 -

The modifications can be made to the bases, the sugars or the linkages of the oligonucleotides. Preferably, the modifications are phosphorothioate (S-ODN) internucleotide linkages, and/or methylphosphonate internucleotide linkages, N'3 - > P5' phosphoramidate linkages, peptide linkages or 2'-methoxyethoxy modifications of the sugar moiety or modifications of the bases. In a preferred embodiment the oligonucleotide has at least two different types of modifications and more preferably at least two different types of internucleotide linkages. In another preferred embodiment the oligonucleotides are linked to or mixed with folic acid, hormones such as steroid hormones or corticosteroids, peptides, proteoglycans, glycolipids, phospholipids or derivatives thereof.

Surprisingly the molecules, obtainable according to the method of the invention could strongly reduce or avoid toxicity and/or non-specific effects of such molecules and/or had significantly higher activity than sequences selected otherwise. Preferably, the molecules according to the invention have the following features: They do not contain four or more consecutive guanosine (N_aGGGGN_b) or inosine ($N_aIIIIIN_b$) residues and the oligonucleotide does not contain two or more series of three or more consecutive guanosine residues ($N_aGGGN_cGGGN_b$) and does not contain two or more series of three or more consecutive inosine residues ($N_aIIIN_cIIIN_b$), wherein N_a , N_b , N_c represent independently oligonucleotides of any sequence having 0 to 20 residues.

In a preferred embodiment the molecule contains a minimum of 10 residues capable of forming either two or three hydrogen bonds per residue. Furthermore, the molecule contains a maximum of 24 consecutive residues linked by phosphorothioate linkages capable of forming either two or three hydrogen bonds per residue. In molecules according to the invention which contain more than 18 residues the additional

- 7 -

linkages preferably consist of methylphosphonate linkages or phosphodiester linkages.

The chemical structures of antisense oligodeoxy-ribonucleotides are given in figure 1.

The chemical structures of antisense oligo-ribonucleotides are given in figure 2. The oligonucleotide is to be understood as a detail out of a longer nucleotide chain.

Of course, the oligonucleotides may be composed of elements of either figures.

In figures 1 and 2, lit. B means an organic base such as adenine (A), guanine (G), cytosine (C), inosine (I), uracil (U) and thymine (T) which are coupled to the deoxyribose. The linkages between the nucleotides are either phosphodiester bonds as in naturally occurring DNA or linkages spacing the nucleotides in such a way to allow hybridization with its target nucleic acid or binding to a protein in order to regulate its activity. such as e.g. phosphorothioate linkages, methylphosphonate linkages, phosphoramidate linkages or peptide linkages.

R_2 and R_3 represent further residues of the oligonucleotide or derivative.

R_4 represents OH or a modification such as a 2'-methoxy ethoxy derivative.


The modifications of the phosphodiester linkage, shown in figures 1 and 2 can be selected from, but are not limited to.

- 8 -

1. Oligodeoxy-ribonucleotides or oligoribionucleotides substituted by

- 1.1 R1 = O
- 1.2 R1 = S
- 1.3. R1 = F
- 1.4. R1 = CH₃
- 1.4. R1 = OEt

2. Oligodeoxy-ribonucleotides where R1 is varied at the internucleotide phosphates within one oligonucleotide



where lit. p stands for the phosphodiester or the phosphoramidate linkage, modified by coupling to R1a, R1b or R1c or for a peptide linkage, or for linkages spacing the nucleotides in such a way to allow hybridization with its target nucleic acid or binding to a protein in order to regulate its activity, structure, function or expression level.

where lit. B = any deoxy-ribonucleotide or ribonucleotide, depending on gene sequence according to the invention.

n, m, x, y = integers 0 - 20

Preferred maximal length of the total number of bases is 30.

2.1	R _{1a} = S	R _{1b} =CH ₃	R _{1c} =S
2.2	R _{1a} = S	R _{1b} =CH ₃	R _{1c} =O
2.2	R _{1a} = S	R _{1b} =O	R _{1c} =S
2.2	R _{1a} = S	R _{1b} =O	R _{1c} =CH ₃
2.3	R _{1a} = CH ₃	R _{1b} =S	R _{1c} =CH ₃
2.4	R _{1a} = CH ₃	R _{1b} =S	R _{1c} =O
2.5	R _{1a} = CH ₃	R _{1b} =O	R _{1c} =CH ₃
2.6	R _{1a} = CH ₃	R _{1b} =O	R _{1c} =S

- 9 -

2.7	$R_{1a} = O$	$R_{1b} = S$	$R_{1c} = O$
2.8	$R_{1a} = O$	$R_{1b} = S$	$R_{1c} = CH_3$
2.9	$R_{1a} = O$	$R_{1b} = CH_3$	$R_{1c} = O$
2.10	$R_{1a} = O$	$R_{1b} = CH_3$	$R_{1c} = S$

Preferably, the oligonucleotide comprises a minimum of 10 elements and a maximum of 24 elements capable of forming either 2 or 3 hydrogen bonds per element. The oligonucleotides of the invention can have modifications to the base, the sugar or the phosphate moiety. Preferred modifications are phosphorothioate (S-ODN) internucleotide linkages, and/or methylphosphonate internucleotide linkages, N'3 -> P5' phosphoramidate linkages, peptide linkages or 2'-methoxyethoxy modifications of the sugar or modifications of the bases. In a very preferred embodiment the antisense oligonucleotides comprise the sequences 41 to 73, 74 to 106, 154 to 172, 173 to 203, 298 to 380, 476 to 506, 519 to 556 and 597 to 641 of figure 3 and 1273 - 1764 of figure 5. A further aspect of the invention is the use of the oligonucleotides of the invention for the inhibition of the genes p53, rb, junD, junB, TGF- β 1, TGF- β 2 to influence cell proliferation, in particular of primary cell cultures such as liver cells, kidney cells, osteoclasts, osteoblasts and/or keratinocytes and/or cells of the blood lineage, such as bone marrow stem cells, and/or progenitor cells of red and white blood cells and/or organ stem cells.

The Sequences 41 - 73 and/or 74 - 106 and/or 154 - 203 and/or 519 - 556 and/or 597 - 641 and/or 1273 - 1277 and/or 1481 - 1490 and/or 1532 - 1549 and/or 1656 are useful for the treatment and/or prevention of immunosuppressive disorders including, but not limited to immunosuppression in neoplastic diseases - including gliomas and other brain tumors, sarcomas, carcinomas and lymphomas - and/or immunosuppression as side effect from drugs, including, but not limited to side effects from cytotoxic agents and/or immunosuppression in AIDS patients.

- 10 -

In a further embodiment of the invention these sequences are also useful for the treatment and/or prevention of hyoproliferation of normal cells, including, but not limited to immune cells, bone marrow stem cells, endothelial cells, organ stem cells and proliferating cells of the intestine.

The Sequences 41 - 73 and/or 74 - 106 and/or 298 - 380 and/or 476 - 506 and/or 519 - 556 and/or 1273 - 1480 and/or 1596 - 1614 and/or 1657 - 1658 and/or 1690 and/or 1696 - 1712 and/or 1751 and/or 1753 - 1754 and/or 1757 are useful for the treatment and/or prevention of hyperproliferative disorders, including but not limited to brain tumors, sarcomas, carcinomas and lymphomas, restenosis, hyperplasia, pulmonary fibrosis, angiogenesis and psoriasis.

The Sequences 1278 - 1480 and/or 1491 - 1531 and/or 1582 - 1595 and/or 1615 - 1655 and/or 1691 - 1694 and/or 1697 - 1750 and/or 1759 - 1764 are useful for the treatment and/or prevention of diseases characterised by hyperfunction of the immune system and/or of inflammatory disorders and/or autoimmune disorders, including, but not limited to asthma (molecules according to the invention being applied by inhalation and/or by parenteral routes and/or orally), multiple sclerosis, inflammatory disorders of the intestine, including jejunitis, ileitis and/or colitis, as well as inflammatory disorders characterised by hyperproliferation and/or hyperfunction of cells of the eosinophilic lineage and/or glomerulonephritis and/or rejection of transplants.

The Sequences 476 - 506 and/or 1550 - 1581 and/or 1582 - 1595 and/or 1658 - 1689 and/or 1691 - 1694 and/or 1713 - 1752 are useful for the treatment and/or prevention of diseases associated with cell degeneration, including, but not limited to neurodegeneration, e.g. Alzheimer's diseases, Parkinson's, ischemic disorders, including myocardial ischemia and/or ischemia of the nervous system, including stroke.

A further aspect of the present invention is a medicament comprising an oligonucleotide according to the invention together with additives. The oligonucleotides of the invention can be used for the preparation of a medicament for the prevention or the treatment of neoplasm, hypoproliferation, hyperproliferation, degenerative diseases, neurodegenerative diseases, ischaemia, disorders of the immune system and/or infectious diseases and can be used for the analysis of gene function or drug target validation.

Molecules according to the invention can be used to study the function of target molecules and their encoded transcription and/or translation products, including RNA molecules and proteins. Downregulations of a protein or nucleic acid molecule using molecules according to the invention can be used to study the function of the molecule. It is also a feature of the invention that molecules according to the invention can be used to study whether modulation of the product has a desired effect, including therapeutic effects and to use this information to develop a different molecule, in order to modulate the function of the protein.

This includes, for example, drug target validation with a molecule according to the invention, in order to answer the question whether development of an agent capable of modulating the structure, function or expression of a potential target molecule, e. g. an agonist or antagonist of the target molecule has desired effect and may e. g. be of therapeutic or diagnostic use.

It is thus also a feature of the invention that molecules according to the invention can be used for drug target validation, including but not limited to studying whether modulation of a protein or nucleic acid molecule has a desired effect, including therapeutic effects and using this information to develop a compound, e. g. a therapeutic compound capable of modulating the structure, function or

- 12 -

expression of the molecule the function of which was previously studied with molecules according to the invention.

Example 1

Treatment of Peripheral blood mononuclear cells with TGF- β 1 antisense phosphorothioate oligodeoxynucleotides:

Human peripheral blood mononuclear cells (PBMCs) produce transforming growth factor β 1 (TGF- β 1). The TGF- β 1 produced by these cells negatively regulates immune cell proliferation in an autologous manner. This autologous negative regulation of immune cell proliferation could be reversed by antisense TGF- β 1 molecules according to the invention, leading to stimulation of immune cell proliferation. In contrast to the molecules according to the invention, antisense molecules chosen conventionally, including that published by Hatzfeld et al. (1991) did not stimulate immune cell proliferation. Even more surprising, several sequences, chosen conventionally, even reduced immune cell proliferation.

Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood of healthy donors by mixing with an equal volume of RPMI 1640 medium (Gibco) supplemented with 10 % fetal calf serum and 1 mM L-glutamine, followed by layering onto Ficoll-Hypaque (Pharmacia) gradients and centrifugation at 400 g for 30 min. PBMCs were removed from the plasma-Ficoll interface and washed in the above medium. Cells (2×10^4 in 100 μ l of medium) were plated into 96 well flat-bottom microtiter plates (Nunc) in serum supplemented complete medium. Cells were activated with 3 μ g/ml phytohemagglutinin and incubated with either no oligodeoxynucleotide (untreated control cells) or with 8 μ M of different antisense phosphorothioate oligodeoxynucleotides, complementary to different regions of the human TGF- β 1 mRNA for 4 days. Cells were then stained with trypan blue to determine cell viability and counted in a Neubauer counting chamber.

- 13 -

Oligonucleotide sequences were either 33 sequences according to the invention, named sequences TGF- β 1-1 - TGF- β 1-33 or the TGF- β 1 antisense sequence from Hatzfeld et al. (1991), J. Exp. Med., 174, pp. 925 - 929 or 39 other conventionally chosen antisense sequences complementary to human TGF- β 1 mRNA, named N1 - N39 (see figure 3).

Surprisingly the molecules according to the invention were much more effective than antisense TGF- β 1 molecules that were chosen conventionally.

Sequences TGF- β 1-1 - TGF- β 1-33 (see figure 3) enhanced lymphocyte proliferation to between 135 and 213% of untreated controls. In contrast, treatment with the antisense sequence from document Hatzfeld et al. reduced proliferation to 62,8%.

Cells treated with the conventionally chosen TGF- β 1 antisense sequences N1 - N39 surprisingly not only failed to increase lymphocyte proliferation, but several of these sequences even revealed a marked inhibition of cell proliferation to between 51,4% and 77% of controls (sequences N1- N14, N20, N26 and N30 - N39). The antisense TGF- β 1 sequences N15 - N19, N21 - N25, N28 and N29 showed neither significant enhancement nor significant inhibition of cell proliferation with values between 94% and 103%. Sequence N27 showed slight toxicity with a reduction in cell proliferation to 88%.

Inhibition of cell proliferation by some of the TGF- β 1 sequences suggests that they may not be merely ineffective, but also toxic. Analysis of the 26 sequences N1- N14, N20, N26 and N30 - N39 revealed that 23 of them contained either 2 or more sequence motifs with three consecutive Gs (hereafter called GGG motif) or at least one motif with 4, 5, or 6 Gs (motifs GGGG, GGGGG, or GGGGGG). Analysis of the sequence from Hatzfeld et al., which also inhibited PBMC proliferation, surprisingly showed that it too contains a GGGGG plus a GGG motif. The 3 toxic sequences that contained

- 14 -

neither 2 GGG motifs nor a motif of 4 or more consecutive Gs, i.e. sequences N8, N26, and N35 were found have a base content with 11 - 13 G-bases per sequence.

In contrast to the sequences from Hatzfeld et al., N1- N14, N20, N26 and N30 - N39 the sequences TGF- β 1-1 - TGF- β 1-33 showed a G-content of maximally 6 G-bases, no combination of two GGG motifs within a single sequence and no GGGG, GGGGG or GGGGGG motif. Since the TGF- β 1 mRNA contains more than 85 target regions for a GGG antisense motif and more than 34 target regions for a GGGG antisense motif, this finding in the sequences according to the invention was highly unlikely on a statistical basis.

The non-effective sequences N15 - N19, N21 - N25, N28 and N29 were found to contain a different base content from both the toxic and the effective sequences: They content of the bases A and T taken together (A/T-content) ranged from 14,3% to 28,5%. These sequences neither enhanced nor did they inhibit PBMC proliferation. Thus, they appeared to be neither effective nor toxic. In contrast to these non-effective sequences with an A/T content of 14,3% - 28,5%, the effective sequences TGF- β 1-1 - TGF- β 1-33 were found to have an A/T content of between 33% - 71,4%.

A further difference between the sequences of the invention and two thirds of the other sequences was found with respect to non-specific protein binding: Sequences from document Hatzfeld et al. and N1- N14, N20, N26 and N30 - N39 were found to show markedly enhanced non-specific protein binding compared to the sequences of the invention.

Sequences from Hatzfeld et al. (H) and N1 - N39 are shown in figure 3 as well as TGF- β 1 antisense sequences according to the invention.

- 15 -

The finding that, while the sequences TGF- β 1-1 - TGF- β 1-33 stimulated proliferation of PBMC immune cells, the sequence from Hatzfeld et al. and sequences N1- N39 where either non-effective with little alteration in PBMC proliferation or had toxic effects and inhibited PBMC proliferation was extended to further antisense sequences both of TGF- β 2 and other genes as detailed in the following examples 2 - 7.

The sequences of the oligonucleotides related with TGF- β 1 are listed in figure 3 for the sake of ease of readability.

For certain applications, including, but not limited to application in dividing cells, including tumor cells, nucleic acid or functional or structural analogs or effective derivatives thereof according to the invention were coupled to folic acid, either at one of the carboxy-groups or at one of the nitrogen atoms of the folic acid.

Furthermore, for certain applications, nucleic acid or functional or structural analogs or effective derivatives thereof according to the invention are mixed with and/or coupled to hormones, steroid hormones such as oestrogen, progesterone, corticosteroids, mineralocorticoids, androgens, phospholipids, peptides, proteoglycans, glycolipids and derivatives therefrom. Preferably, a coupling occurs at R² and/or R³ of figures 1 and 2.

Example 2

p53 antisense nucleic acids (figure 3 shows the respective oligonucleotides)

p53 is a tumor suppressor gene that negatively regulates cell proliferation. Certain mutations in the gene can alter the function of p53 in such a way that it becomes an oncogene. The effects of p53 antisense oligodeoxynucleotides on cells

- 16 -

containing wild type p53 was analyzed and subsequently also the effect of these sequences on cells with mutated p53.

In cells with wild type p53 effective antisense nucleic acids will lead to downregulation of the wild type p53 protein and thus to enhanced proliferation of the treated cells. Molecules according to the invention are named p53-1 - p53-33. Noneffective p53 antisense sequences were named p53-N-1 - p53-N-18. Toxic sequences, which inhibited proliferation instead of enhancing it as do effective p53 antisense sequences were named p53-T-1 - p53-T-29.

Normal human fibroblasts were grown in RPMI medium supplemented with 5% fetal calf serum (FCS) and 2500 cell/well were plated into 96-well microtiter plates. Antisense phosphorothioate oligonucleotides were added at 2 μ M concentration after 2 h.

Two assays to determine cell proliferation were performed:

- To determine 3H-thymidine incorporation, cells were incubated before harvesting with 0,15 μ Ci 3H-thymidine/well for 6 h. Cells were lysed by freezing, spotted onto glass filters and the amount of incorporated tritium was determined by liquid scintillation counting.
- To determine cell number, cells were stained with trypan blue and counted in a Neubauer counting chamber.

Surprisingly, only treatment of cells with antisense sequences according to the invention (p53-1 - p53-33) resulted in an increase in thymidine incorporation to between 3- and 9-fold.

In contrast, treatment with noneffective sequences (p53-N-1 - p53-N-18) did not result in significant alterations in thymidine incorporation.

- 17 -

Furthermore, treatment with toxic antisense p53 sequences (p53-T-1- p53-T-29) resulted in a decrease in proliferation instead of an increase.

In summary, the 33 antisense sequences according to the invention resulted in effective downregulation of negative growth control by p53 and increased cell proliferation, while the 47 other antisense sequences had either no significant effect on cell proliferation or even suppressed cell proliferation.

Example 3

junB antisense nucleic acids (figure 3 shows the respective oligonucleotides)

junB and junD, two genes encoding transcription factors of the jun gene family are negative regulators of cell growth, like p53. The effects of different junB and junD antisense oligodeoxynucleotides was analyzed.

Effective junB and JunD antisense nucleic acids will lead to downregulation of the JunB and JunD proteins respectively and thus to enhanced proliferation of the treated cells. Antisense molecules according to the invention are named JunB-1 - JunB-19 and JunD-1 - JunD-31. Noneffective junB antisense sequences were named JunB-N-1 - JunB-N-57. Toxic sequences, which inhibited proliferation instead of enhancing it were named JunB-T-1- JunB-T-20 and JunD-T-1 - JunD-T-17.

Normal human fibroblasts were grown in RPMI medium supplemented with 5% fetal calf serum (FCS) and 2500 cell/well were plated into 96-well microtiter plates. Antisense phosphorothioate oligonucleotides were added at 2 μ M concentration after 2 h.

- 18 -

Two assays to determine cell proliferation were performed:

- To determine ³H-thymidine incorporation, cells were incubated before harvesting with 0,15 μ Ci ³H-thymidine/well for 6 h. Cells were lysed by freezing, spotted onto glass filters and the amount of incorporated tritium was determined by liquid scintillation counting.
- To determine cell number, cells were stained with trypan blue and counted in a Neubauer counting chamber.

Surprisingly, again only treatment of cells with antisense sequences according to the invention (JunB-1 - JunB-19 and JunD1- JunD31) resulted in an increase in thymidine incorporation to between 2- and 7-fold.

In contrast, treatment with noneffective sequences (JunB-N-1 - JunB-N-57) did not result in significant alterations in thymidine incorporation.

Furthermore, treatment with toxic antisense junB or JunD sequences (JunB-T-1- JunB-T-20 and JunD-T-1 - JunD-T-17) resulted in a decrease in proliferation instead of an increase.

In summary, the 50 antisense sequences according to the invention resulted in effective downregulation of negative growth control by JunB and JunD , while the 94 other antisense sequences had either no significant effect on cell proliferation or were even toxic.

Example 4 (figure 3 shows the respective oligonucleotides)

erbB-2, is a transmembrane molecule with an intracellular tyrosine kinase activity that is amplified and/or overexpressed by carcinoma cells in a variety of neoplasms including breast cancer, lung cancer, oesophageal and gastric

- 19 -

cancer, bile duct carcinoma, bladder cancer, pancreatic cancer and ovarian cancer.

In several of these tumors, an amplification and overexpression of the c-erbB-2 gene in the tumor tissue has been shown to correlate with a poor clinical prognosis. Overexpression of p185erbB-2 in non-small-cell lung carcinoma has been shown to impart resistance to a number of chemotherapeutic agents.

Effective erbB-2 antisense nucleic acids will lead to downregulation of the erbB-2 protein and in overexpressing tumor cell lines will lead to reduced cell proliferation of the treated cells. Antisense molecules according to the invention are named erbB-2-1 - erbB-2-83. Noneffective erbB-2 antisense sequences were named erbB-2-N-1 - erbB-2-N-95.

erbB-2 overexpressing SK-Br-3 human mammary carcinoma cells were grown in RPMI medium supplemented with 5% fetal calf serum (FCS) and 2500 cell/well were plated into 96-well microtiter plates. Antisense phosphorothioate oligonucleotides were added at 2 μ M concentration after 2 h.

To determine erbB-2 protein expression cells were harvested with a cell scraper and subjected to ELISA protein determination.

Only treatment of cells with antisense sequences according to the invention (erbB-2-1 - erbB-2-83) resulted in a significant reduction in erbB-2 protein expression by 40-95%.

In contrast, treatment with noneffective sequences (erbB-2-N-1 - erbB-2-N-95) did not result in significant alterations in erbB-2 protein expression.

To determine cell number, cells were stained with trypan blue and counted in a Neubauer counting chamber.

- 20 -

Only treatment of cells with antisense sequences according to the invention (erbB-2-1 - erbB-2-83) resulted in a reduction in cell number by 35-70%.

In contrast, treatment with noneffective sequences (erbB-2-N-1 - erbB-2-N-95) did not result in significant alterations in cell proliferation.

erbB-2 antisense sequences were shown in figure 3-8 to 3-11

Example 5 (figure 3 shows the respective oligonucleotides)

The c-fos gene encodes an immediate early gene type transcription factor. Effective c-fos antisense nucleic acids will lead to downregulation of the c-Fos protein.

Antisense molecules according to the invention are named c-fos-1 - c-fos-31. Noneffective c-fos antisense sequences were named c-fos-N-1 - c-fos-N-12.

Normal human fibroblasts were grown in RPMI medium supplemented with 5% fetal calf serum (FCS) and 2500 cell/well were plated into 96-well microtiter plates. Antisense phosphorothioate oligonucleotides were added at 2 μ M concentration after 2 h.

Expression of the c-Fos protein was determined by ELISA in cell lysates.

Only treatment of cells with antisense sequences according to the invention (c-fos-1 - c-fos-31) resulted in a significant reduction in c-fos protein expression by 45-95%.

In contrast, treatment with noneffective sequences (c-fos-N-1 - c-fos-N-12) did not result in significant alterations in c-Fos protein expression.

- 21 -

Example 6 (figure 3 shows the respective oligonucleotides)

TGF- β 2, like TGF- β 1 is a member of the transforming growth factor- β family of cytokines.

Overexpression of TGF- β 1 and TGF- β 2 is linked to malignant progression, immunosuppression and escape of the tumors from surveillance by the immune system.

Effective TGF- β 2 antisense nucleic acids will lead to downregulation of the TGF- β 2 growth factor.

Antisense molecules according to the invention are named TGF- β 2-1 - TGF- β 2-38. Noneffective TGF- β 2 antisense sequences were named TGF- β 2-N-1 - TGF- β 2-N-40.

TGF- β 2 overexpressing tumor cells were grown in RPMI medium supplemented with 5% fetal calf serum (FCS) and 2500 cell/well were plated into 96-well microtiter plates. Antisense phosphorothioate oligonucleotides were added at 2 μ M concentration after 2 h.

TGF- β 2 protein expression was determined by ELISA, both in the supernatant and in cell lysates.

Only treatment of cells with antisense sequences according to the invention (TGF- β 2-1 - TGF- β 2-38) resulted in a significant reduction in TGF- β 2 protein expression by 35-80%.

In contrast, treatment with noneffective sequences (TGF- β 2-N-1 - TGF- β 2-N-40) did not result in significant alterations in TGF- β 2 protein expression.

- 22 -

Example 7 (figure 3 shows the respective oligonucleotides)

rb antisense nucleic acids

rb is a tumor suppressor gene that negatively regulates cell proliferation. The effects of rb antisense oligodeoxynucleotides on cells containing wild type rb was analyzed.

In cells with wild type rb effective antisense nucleic acids will lead to downregulation of the wild type rb protein and thus to enhanced proliferation of the treated cells. Molecules according to the invention are named rb-1 - rb-45. Noneffective rb antisense sequences were named -1 - rb-N-168. Toxic sequences, which inhibited proliferation instead of enhancing it as do effective rb antisense sequences were named rb-T-1- rb-T-16.

Normal human fibroblasts were grown in RPMI medium supplemented with 5% fetal calf serum (FCS) and 2500 cell/well were plated into 96-well microtiter plates. Antisense phosphorothioate oligonucleotides were added at 2 μ M concentration after 2 h.

Two assays to determine cell proliferation were performed:

- To determine 3H-thymidine incorporation, cells were incubated before harvesting with 0,15 μ Ci 3H-thymidine/well for 6 h. Cells were lysed by freezing, spotted onto glass filters and the amount of incorporated tritium was determined by liquid scintillation counting.
- To determine cell number, cells were stained with trypan blue and counted in a Neubauer counting chamber.

Surprisingly, only treatment of cells with antisense sequences according to the invention (rb-1 - rb-45) resulted in an increase in thymidine incorporation to between 2- and 6-fold.

- 23 -

In contrast, treatment with noneffective sequences (rb-N-1 - rb-N-168) did not result in significant alterations in thymidine incorporation.

Furthermore, treatment with toxic antisense rb sequences (rb-T-1- rb-T-16) resulted in a decrease in proliferation instead of an increase.

In summary, the 45 antisense sequences according to the invention resulted in effective downregulation of negative growth control by rb and increased cell proliferation, while the 184 other antisense sequences had either no significant effect on cell proliferation or even suppressed cell proliferation.

Example 8

Oligonucleotide sequences according to the invention were synthesized with various different backbone modifications: Exemplary results are given below.

For the sequence

erbB-2-42: CATCTGGAACTTCCAGATG

the following chemical modifications were tested in erbB-2 overexpressing carcinoma cells:

1. S-ODN erbB-2-42 (i.e. all backbone linkages were thioate modifications).

C-pS-A-pS-T-pS-C-pS-T-pS-G-pS-G-pS-A-pS-A-pS-A-pS-C-pS-T-pS-T-pS-C-pS-C-pS-A-pS-G-pS-A-pS-T-pS-G

- 24 -

2. Me-ODN/S-ODN/Me-ODN erbB-2-42 (i.e. Linkages at the 5' and 3' end were methylphosphonate linkages while linkages in the middle were thioate modifications as follows):

C-pMe-A-pMe-T-pS-C-pS-T-pS-G-pS-G-pS-A-pS-A-pS-A-pS-C-pS-T-
pS-T-pS-C-pS-C-pS-A-pS-G-pS-A-pMe-T-pMe-G

or

C-pMe-A-pMe-T-pMe-C-pS-T-pS-G-pS-G-pS-A-pS-A-pS-A-pS-C-pS-T-
pS-T-pS-C-pS-C-pS-A-pS-G-pMe-A-pMe-T-pMe-G

or

C-pMe-A-pMe-T-pMe-C-pMe-T-pS-G-pS-G-pS-A-pS-A-pS-A-pS-C-pS-T-
pS-T-pS-C-pS-C-pS-A-pMe -G-pMe-A-pMe-T-pMe-G

or

C-pMe-A-pMe-T-pMe-C-pMe-T-pMe-G-pMe-G-pS-A-pS-A-pS-A-pS-C-pS-
T-pS-T-pS-C-pMe-C-pMe-A-pMe-G-pMe-A-pMe-T-pMe-G

3. Me-ODN / S-ODN erbB-2-42 (i.e. Linkages at the 5' end were methylphosphonate linkages while linkages at the 3' were thioate modifications as follows):

C-pMe-A-pMe-T-pMe-C-pMe-T-pMe-G-pMe-G-pMe-A-pMe-A-pMe-A-pS-C-
pS-T-pS-T-pS-C-pS-C-pS-A-pS-G-pS-A-pS-T-pS-G

4. S-ODN / Me-ODN erbB-2-42 (i.e. Linkages at the 5' end were methylphosphonate linkages while linkages at the 3' were thioate modifications as follows):

C-pS-A-pS-T-pS-C-pS-T-pS-G-pS-G-pS-A-pS-A-pS-A-pMe-C-pMe-T-
pMe-T-pMe-C-pMe-C-pMe-A-pMe-G-pMe-A-pMe-T-pMe-G

5. Me-ODN erbB-2-42 (i.e. linkages methylphosphonate linkages):

C-pMe-A-pMe-T-pMe-C-pMe-T-pMe-G-pMe-G-pMe-A-pMe-A-pMe-A-C-
pMe-T-pMe-T-pMe-C-pMe-C-pMe-A-pMe-G-pMe-A-pMe-T-pMe-G

- 25 -

6. pN/S-ODN/pN erbB-2-42 (i.e. Linkages at the 5' and 3' end were phosphoramidate linkages while linkages in the middle were thioate modifications as follows):

C-pN-A-pN-T-pS -C-pS-T-pS-G-pS-G-pS-A-pS-A-pS-A-pS-C-pS-T-pS-
T-pS-C-pS-C-pS-A-pS-G-pS-A-pN-T-pN-G

or

C-pN-A-pN-T-pN-C-pS-T-pS-G-pS-G-pS-A-pS-A-pS-A-pS-C-pS-T-pS-
T-pS-C-pS-C-pS-A-pS-G-pN-A-pN-T-pN-G

or

C-pN-A-pN-T-pN-C-pN -T-pS-G-pS-G-pS-A-pS-A-pS-A-pS-C-pS-T-pS-
T-pS-C-pS-C-pS-A-pN -G-pN-A-pN-T-pN-G

or

C-pN-A-pN-T-pN-C-pN -T-pN -G-pN -G-pS-A-pS-A-pS-A-pS-C-pS-T-
pS-T-pS-C-pN -C-pN-A-pN -G-pN-A-pN-T-pN-G

where

pS stands for substitution of one of the non-bridging oxygen atoms of the backbone linkage with a sulfur atom, while pMe stands for substitution of one of the non-bridging oxygen atoms of the backbone linkage with a methyl group.

pN stands for a N3'→P5' phosphoramidate linkage.

Also a combination of linkages (N-pS-N-pO-N-pO-N)_n-[pS-N]_m wherein n = 1 - 10 and m = 0 - 6 where N stand for any nucleotide or structural or functional analog or derivative thereof.

While the Me-ODN backbone modification strongly reduced the erbB-2 activity of the erbB-2-42 sequence to less than 20%, backbone modifications 1.-4. had strong erbB-2 inhibitory capacity with an inhibition of erbB-2 protein expression by between 78% and 89% at 2 μM concentration at 48 h after the beginning of treatment of overexpressing carcinoma cells. While the pure S-ODN had the highest suppression capacity with 89%, the Me-ODN/S-ODN/Me-ODN as well as the Me-ODN/S-ODN

- 26 -

and S-ODN/Me-ODN and pN/S-ODN/pN, displayed reduced protein binding and when tested for complement activation, showed reduced complement activation. These characteristics are advantageous for certain applications e.g. intravenous systemic application in vivo.

Example 9

Similar effects were obtained when testing other sequences according to the invention with the above backbone modifications.

Inhibition of TGF-beta-1 gene expression with the effective sequences for TGF-beta-1 according to the invention was highest with S-ODN and the Me-ODN/S-ODN/Me-ODN backbone modifications and lowest with the Me-ODN modification, while protein binding and complement activation were reduced in sequences containing Me-ODN linkages.

Example 10

Surprisingly, effectivity of sequences according to the invention was significantly improved in various cell types by coupling nucleic acids according to the invention to folic acid:

erbB-2 inhibitory capacity which was relatively low after 24 h compared to 48 h with an inhibition of erbB-2 protein synthesis by 24-37% was markedly increased by coupling sequences according to the invention to folic acid to 48-62% at 2 μ M concentration 24 h after the beginning of treatment of overexpressing carcinoma cells.

Similar effects were achieved by coupling sequences according to the invention to folic acid derivatives including aminopterin and amethopterin.

Example 11

Surprisingly, effectivity of sequences according to the invention was strongly improved by coupling oligonucleotides according to the invention to cortisol:

Cellular uptake and inhibitory capacity of sequences according to the invention including sequences for TGF-beta-1, TGF-beta-2, c-fos, p53, erbB-2, rb, c-fos, junB, junD, c-jun, MIP-1 alpha, JAK-2, bcl-2 and were markedly increased by coupling cortisol either to the 3' or 5' hydroxyl groups of oligonucleotide sequences according to the invention.

Example 12

Effectivity of sequences according to the invention was also strongly improved in various cell types by coupling nucleic acids according to the invention to or mixing them with other steroid hormones and their derivatives, including oestrogens, anti-oestrogens, prednisone, prednisolone, androgens, anti-androgens, gestagens like progesterone as well as peptides, proteoglycans, glycolipids, phospholipids and derivatives therefrom.

Androgens, particularly androstendion and testosterone, as well as anti-androgens, including cyproteronacetate, flutamide, anandron, linked to the nucleic acids increased effectiveness of the molecules in various cell types including prostatic carcinoma cells.

Oestrogens, anti-oestrogens and their derivatives, including fosfestrol, toremifen, ethinyloestradiol, diethylstilboestole and the oestradiol derivatives oestradiol-benzoate, oestradiol-valerate and oestradiol-undecylate, as well as progesterone and its derivatives, including medroxyprogesteroneacetate and megestrolacetate linked to the oligonucleotides strongly enhanced activity of the molecules according

- 28 -

to the invention in various cell types including mammary carcinoma cells.

- 29 -

C l a i m s

1. A method for the preparation of an antisense oligonucleotide or derivative thereof comprising the steps of
 - selecting a target nucleic acid, if necessary elucidating its sequence
 - generating the antisense oligonucleotide with the proviso that
 - the oligonucleotide comprises at least 8 residues,
 - the oligonucleotide comprises at maximum twelve elements, which are capable of forming three hydrogen bonds each to cytosine bases,
 - the oligonucleotide does not contain four or more consecutive elements, capable of forming three hydrogen bonds each with four consecutive cytosine bases (CCCC) within the target molecule or alternatively four or more consecutive elements of GGGG,
 - the oligonucleotide does also not contain 2 or more series of three consecutive elements, capable of forming three hydrogen bonds each with three consecutive cytosine bases (CCC) within the target molecule, or alternatively 2 or more series of three consecutive elements of GGG, and
 - the ratio between residues forming two hydrogen bonds per residue (2H-bond-R) with the target molecule and those residues forming three hydrogen bonds per residue (3H-bond-R) with the target molecule, is ruled by the following specifications:

3H-bond-R

 ≥ 0.29

 3H-bond-R + 2H-bond-R

- and synthesizing the oligonucleotide thus generated in a per se known manner.

- 30 -

2. The method according to claim 1, wherein the generated oligonucleotide complies with the following specification

$$\frac{3\text{H-bond-R}}{3\text{H-bond-R} + 2\text{H-bond-R}} = 0.33 \text{ to } 0.86$$

3. The method according to any one of the claims 1 or 2, wherein the generated oligonucleotides are modified for higher nuclease resistance than naturally occurring oligo- or polynucleotides.
4. The method according to claim 3, wherein the generated oligonucleotides are modified at the bases, the sugars or the linkages of the oligonucleotides, preferably by phosphorothioate (S-ODN) internucleotide linkages, and/or methylphosphonate internucleotide linkages, N'3 -> P5' phosphoramidate linkages, peptide linkages or 2'-methoxyethoxy modifications of the sugar or modifications of the bases.
5. The method according to claim 3 and/or 4, wherein the oligonucleotide has at least two different types of modifications.
6. The method according to any one of the claims 1 to 5, wherein the oligonucleotides are reacted with folic acid, hormones such as steroid hormones or corticosteroides or derivatives thereof by linking the oligonucleotides covalently to or mixing with folic acid, hormones such as steroid hormones or corticosteroides, peptides, proteoglycans, glycolipids or phospholipids.

- 31 -

7. An antisense oligonucleotide or derivative thereof obtainable according to the method according to any one of the claims 1 to 6 except oligonucleotides represented by Fig. 4.
8. The oligonucleotide or derivative of claim 7, which does not contain four or more consecutive guanosine (N_aGGGGN_b) or inosine ($N_aIIIIIN_b$) residues and the oligonucleotide does not contain two or more series of three or more consecutive guanosine residues ($N_aGGGN_cGGGN_b$) and does not contain two or more series of three or more consecutive inosine residues ($N_aIIIN_cIIIN_b$), wherein N_a , N_b , N_c represent independently nucleotides or oligonucleotides or derivatives thereof having 0 to 20 residues.
9. The oligonucleotide or derivative of claims 7 and/or 8, comprising a minimum of ten elements and a maximum of 24 elements capable of forming either two or three hydrogen bonds per element.
10. The oligonucleotide or derivative according to any one of the claims 7 to 9, having modifications at the bases, the sugars or the phosphate moieties of the oligonucleotides.
11. The oligonucleotide or derivative of any one of the claims 7 to 10, wherein the modifications are phosphorothioate (S-ODN) internucleotide linkages, and/or methylphosphonate internucleotide linkages, N'3 -> P5' phosphoramidate linkages, peptide linkages or 2'-methoxyethoxy modifications of the sugar or modifications of the bases.



- 32 -

12. The oligonucleotide or derivative of any one of the claims 7 to 11 coupled to or mixed with folic acid, hormones, steroid hormones such as oestrogene, progesterone, corticosteroids, mineral corticoids, peptides, proteoglycans, glycolipids, phospholipids and derivatives therefrom.
13. The oligonucleotide according to any one of the claims 7 to 12, wherein the antisense oligonucleotide against the TGF- β 1 gene comprise the sequences 41 to 73 of Fig. 3, the oligonucleotides against the gene p53 comprising the sequences 74 to 106 of Fig. 3, the antisense oligonucleotides against junB comprising the sequences 154 to 172 of Fig. 3, the antisense oligonucleotides against junD comprising the sequences 173 to 203 of Fig. 3, the antisense oligonucleotides against the erbB-2 gene comprise the sequences 298 to 380 of Fig. 3, the antisense oligonucleotides against c-fos genes comprise the sequences 476 - 506 of Fig. 3; the antisense oligonucleotides against the gene TGF- β 2 comprise the sequences 519 to 556 of Fig. 3 as well as the antisense oligonucleotides against the gene rb comprise the sequences 597 to 641 of Fig. 3.; as well as sequences 1273 to 1764. of Fig. 5.
14. A composition comprising an oligonucleotide or derivative according to any one of the claims 7 to 13 for the manufacturing of a medicament or a composition for the inhibition of the genes p53, rb, junD, junB, TGF- β 1, TGF- β 2 to influence cell proliferation, in particular of primary cell cultures such as liver cells, kidney cells, osteoclasts, osteoblasts and/or keratinocytes and/or cells of the blood lineage, such as bone marrow stem cells, and/or progenitor cells of red and white blood cells.


- 33 -

15. A medicament comprising an oligonucleotide according to any one of the claims 7 to 13 together with additives.
16. The use of the oligonucleotides according to any of the claims 7 to 13 for the preparation of a medicament for the prevention or the treatment of neoplasm, hypoproliferation, hyperproliferation, degenerative diseases, neurodegenerative diseases, ischaemia, disorders of the immune system and/or infectious diseases, and/or metabolic dysfunctions.
17. The use of the oligonucleotides according to any one of the claims 7 to 13 for the analysis of gene function or drug target validation.


1 / 36




Adenine



Guanine




Cytosine




Thymine

Fig. 1


2 / 36




Adenine



Guanine



Cytosine



Uracil

FIG. 2

1.	A3	CCCGGAGGGCGGCATGGGGGA
2.	N1	CCTCAGGGAGAAGGGGCGC
3.	N2	GTAGGAGGGCCTCGAGGG
4.	N3	CTGCAGGGGCTGGGGGTC
5.	N4	AGGGCTGGTGTGGTGGGG
6.	N5	GGCATGGGGGAGGCGGCG
7.	N6	CCGGAGGGCGGCATGGGG
8.	N7	GGGGGGCTGGCGAGCCGC
9.	N8	GGACAGGATCTGGCCGCGATGG
10.	N9	CCCCCTGGCTCGGGGGGC
11.	N10	GGGCCGGGCGGCACCTCC
12.	N11	GGGCAGCGGGCCGGGCGG
13.	N12	ACGGCCTCGGGCAGCGGG
14.	N13	GGGTGCTGTGTACAGGG
15.	N14	GGGTTCACCAATTAGCACGCGG
16.	N15	TCATAGATTTCGTT
17.	N16	TTGTATAGATT
18.	N17	AAGAACATATATATG
19.	N18	AAGAACATATATAT
20.	N19	TTGAAGAACATATATA
21.	N20	CCGGGAGAGCAACACGGG
22.	N21	ACTTTTAACTTGA
23.	N22	ATTGTGTCTGTATT
24.	N23	ATTGTGTCTGTATT
25.	N24	AATGTGTCTGTATT
26.	N25	AATGTGTCTGTATT
27.	N26	GGCGAGTCGCTGGGTGCCAGCAGCCGG
28.	N27	GGCGAGTCGCTGGG
29.	N28	ACATCAAAAGATAA
30.	N29	TGACATCAAAAGAT
31.	N30	GGGCCCTCTCCAGCGGGG
32.	N31	GGGCTCGGCGGTGCCGGG
33.	N32	GGGGCAGGGCCCGAGGCA
34.	N33	GGCTCCAAATGTAGGGGC
35.	N34	CGGGTTATGCTGGTTGTACAGGGC
36.	N35	CGGCGCCGCGAGGCGCCCGGG
37.	N36	GGGGCGGGGCGGGACC
38.	N37	GGGCGGGGCGGGGCGGGG
39.	N38	GGGCGGGGTGGGGCGGGG
40.	N39	GGGCAAGGCAGCGGGGGCGGGG
41.	TGF- β 1-1	CGGTAGCAGCAGCG
42.	TGF- β 1-2	CCAGTAGCCACAGC
43.	TGF- β 1-3	GCAGGTGGATAGTCC
44.	TGF- β 1-4	CTTGCAAGGTGGATAG
45.	TGF- β 1-5	CGATAGTCTTGCAGG
46.	TGF- β 1-6	CCATGTGATAGTCTTGC
47.	TGF- β 1-7	CTCGATGCGCTTCCG
48.	TGF- β 1-8	CCTCGATGCGCTTCC
49.	TGF- β 1-9	GGATGGCCTCGATGC
50.	TGF- β 1-10	GGACAGGATCTGGCC
51.	TGF- β 1-11	CGCAGCTTGGACAGG
52.	TGF- β 1-12	GAGCCGCGAGCTTGG
53.	TGF- β 1-13	CGAGCCGCGAGCTTG
54.	TGF- β 1-14	ACCTCCCCCTGGCT
55.	TGF- β 1-15	CCACCATTAGCACG
56.	TGF- β 1-16	GAACTTGTATAGATTTC
57.	TGF- β 1-17	GCTGTGTGTAATCTGC
58.	TGF- β 1-18	GCTCCACGTGCTGC
59.	TGF- β 1-19	GAACTGTGTGTATTTTC
60.	TGF- β 1-20	GCCAGGAATTGTTC
61.	TGF- β 1-21	GTGACATCAAAAGATAAC
62.	TGF- β 1-22	GGCTCAACCACTGCC
63.	TGF- β 1-23	GCTGTACAGGAGC
64.	TGF- β 1-24	CCTGTGTACAGG
65.	TGF- β 1-25	GCAGTGTGTATCCCTGC
66.	TGF- β 1-26	GCAGTGTGTATCCC

Fig. 3 - 1

4 / 36

67.	TGF- β 1-27	CCAGGTACCTCGG
68.	TGF- β 1-28	GCCATGAATGGTGGC
69.	TGF- β 1-29	GCCATGAATGGTGG
70.	TGF- β 1-30	CCATGAGAAGCAGG
71.	TGF- β 1-31	GGAAGTCAATGTACAGC
72.	TGF- β 1-32	CCACGTAGTACACGATGG
73.	TGF- β 1-33	GCACTTGCAGGAGC
74.	p53-1	CCATGGCAGTGACC
75.	p53-2	GGCTCCTCCATGGC
76.	p53-3	GCTAGGATCTGACTGC
77.	p53-4	CCTGACTCAGAGGG
78.	p53-5	GGTCTGAAAATGTTTCC
79.	p53-6	CCATTGCTTGGGACGG
80.	p53-7	GCATCAAATCATCC
81.	p53-8	CCATTGTTCAATATCG
82.	p53-9	GGTCTTCAGTGAACC
83.	p53-10	GGAGCTTCATCTGGACC
84.	p53-11	CCTCTGGCATTCTGG
85.	p53-12	AGGGACAGAAGATG
86.	p53-13	GTTTTCTGGGAAGG
87.	p53-14	GGTTTTCTGGGAAG
88.	p53-15	AGGTTTTCTGGGAAG
89.	p53-16	GTAGGTTTTCTGGG
90.	p53-17	GGTAGGTTTTCTGG
91.	p53-18	CCAGAATGCAAGAAGCC
92.	p53-19	GCTGTCCCAGAATGC
93.	p53-20	GCAAGTCACAGACTTGGC
94.	p53-21	CCACAGCTGCACAGG
95.	p53-22	GGTGTGGAATCAACC
96.	p53-23	GTCATGTGCTGTGA
97.	p53-24	CGCTATCTGAGCAGCG
98.	p53-25	CCAGTGTGATGATGG
99.	p53-26	CCAGTAGATTACCACTGG
100.	p53-27	GGCACAACACGCACC
101.	p53-28	CCACGGATCTGAAGG
102.	p53-29	CGGAACATCTCGAAGCG
103.	p53-30	CCTCATTACGCTCTCGG
104.	p53-31	CCTTGAGTTCCAAGG
105.	p53-32	CCTTTTTGGACTTCAGG
106.	p53-33	GGAGGTAGACTGACCC
107.	p53-N-1	AAAATGTTTCTT
108.	p53-N-2	TGAAAATGTTTC
109.	p53-N-3	CTGAAAATGTTT
110.	p53-N-4	TCTGAAAATGTTT
111.	p53-N-5	TCTGAAAATGTT
112.	p53-N-6	AAATCATCCATT
113.	p53-N-7	TTGTTCAATATC
114.	p53-N-8	ATTGTTCAATATC
115.	p53-N-9	ATTGTTCAATAT
116.	p53-N-10	CATTGTTCAATAT
117.	p53-N-11	CATTGTTCAATA
118.	p53-N-12	AAAAGTGTTCCT
119.	p53-N-13	ACATGAGTTTTTTAT
120.	p53-N-14	AACATGAGTTTTTTAT
121.	p53-N-15	ACATGAGTTTTTTA
122.	p53-N-16	AACATGAGTTTTTTA
123.	p53-N-17	AACATGAGTTTTTTT
124.	p53-N-18	AAAACATCTTGTT
125.	p53-T-1	CAGAGGGGGCTCGACGC
126.	p53-T-2	CTGACTCAGAGGGGGCTC
127.	p53-T-3	AGGGGGACAGAACG
128.	p53-T-4	TTGGGACGGCAAGGGGACAGAA
129.	p53-T-5	TGGGACGGCAAGGGGGA

Fig. 3 - 2

5 / 36

130.	p53-T-6	GCCACGGGGGAGCA
131.	p53-T-7	GCAGGGGCCACGGGGGAG
132.	p53-T-8	AGGGGCCACGGGG
133.	p53-T-9	CAGGGGCCACGGGG
134.	p53-T-10	GGTGCAGGGGCCACG
135.	p53-T-11	TGGTGCAGGGGCCCGCG
136.	p53-T-12	GGGGCTGGTGCAGGGGCC
137.	p53-T-13	AGGGGGCTGGTGCAGGGG
138.	p53-T-14	GGGCTGGTGCAGGG
139.	p53-T-15	GAGGGGGCTGGTGCAG
140.	p53-T-16	AGGAGGGGGCTGGTG
141.	p53-T-17	GGGCCAGGAGGGGGCTGG
142.	p53-T-18	AGGGGCCAGGAGGGGGCT
143.	p53-T-19	GGGGCCAGGAGGGG
144.	p53-T-20	CAGGGGCCAGGAGGG
145.	p53-T-21	TCTGGGAAGGGACAGA
146.	p53-T-22	TGAGGGCAGGGGAGTA
147.	p53-T-23	TTGAGGGCAGGGGAG
148.	p53-T-24	CGGGTGCCGGGCGGGGGTG
149.	p53-T-25	CGGACGCGGGTGCCGGGCGGGGT
150.	p53-T-26	CGGGTGCCGGGCGGG
151.	p53-T-27	GGACGCGGGTGCCGGGCG
152.	p53-T-28	TGGGGGCAGCGCCTCACA
153.	p53-T-29	GGTGGGGCAGCGCCT
154.	JunB-1	CCATTTTAGTGACATCCGG
155.	JunB-2	CCATTTTAGTGACATCC
156.	JunB-3	GCTGTTCATTTTAGTGC
157.	JunB-4	GTAGTCGTGTAGAG
158.	JunB-5	GTTTGTAGTCGTGTAG
159.	JunB-6	GTTTCAGGAGTTTGTAG
160.	JunB-7	CCAGCTCCGAAGAGG
161.	JunB-8	CGTCGTGTGATCAGG
162.	JunB-9	GGTAAAAGTACTGTCC
163.	JunB-10	GGCTTTGACAAAGCC
164.	JunB-11	CTTGTGCAGATCGTCCAG
165.	JunB-12	CGTGGTTTCATCTGTGC
166.	JunB-13	CACGTGGTTTCATCTGTG
167.	JunB-14	CCTCCTTGAAGGTGG
168.	JunB-15	CGCTCCACTTTGATGCG
169.	JunB-16	CCTTGTCTCCAGG
170.	JunB-17	GGTACTCGACAGCC
171.	JunB-18	CTGACGTGGGTCATG
172.	JunB-19	CCGTTGCTGACGTGG
173.	JunD-1	CATCCTCCGCCTCC
174.	JunD-2	GTTTCCATCCTCCG
175.	JunD-3	GGTGTTCATCCTCC
176.	JunD-4	GGTGTTCATCCTC
177.	JunD-5	GCTCAGCGCCTCATC
178.	JunD-6	CCTTCTTCATCATGCTGC
179.	JunD-7	CCTTCTTCATCATGCTG
180.	JunD-8	CCTTCTTCATCATGC
181.	JunD-9	GGGTCTTCTTCATCATGC
182.	JunD-10	CCTGCTCACTCAGG
183.	JunD-11	CGCAGGCTTGAGCG
184.	JunD-12	GCCAGCTTCAGCAGC
185.	JunD-13	GGTGGTGACCAGCC
186.	JunD-14	CCTGGCGAACTCC
187.	JunD-15	GCTTGTGTAAATCC
188.	JunD-16	GGTTCTGCTTGTGTAAATCC
189.	JunD-17	GCTGCTCAGGTTGCG
190.	JunD-18	GAAGGCGACCGTCG
191.	JunD-19	CGAAGGCGACCGTC
192.	JunD-20	GCACCGTCTGTGGC
193.	JunD-21	CGTGTCCATGTCGATGG
194.	JunD-22	CGTGTCCATGTCGATG

Fig. 3 - 3

6 / 36

195.	JunD-23	GCGTGTCCATGTGG
196.	JunD-24	CCAGCTTGCGCTTGC
197.	JunD-25	CGCTCCAGCTTGGG
198.	JunD-26	CGTGTCTCTGACTCTTGAG
199.	JunD-27	CGTGTCTCTGACTCTTG
200.	JunD-28	GCTGTGTGACGTGGC
201.	JunD-29	CGACTCAGTACGCC
202.	JunD-30	GCCATGCCCGACTC
203.	JunD-31	CCCTTGGAGGTGGC
204.	JunB-N-1	TTTTAGTGCACAT
205.	JunB-N-2	TGTTCCATTTTAGT
206.	JunB-N-3	AAAAAAGTGGAG
207.	JunB-N-4	TACAAAAAAGTG
208.	JunB-N-5	ATACAAAAAAGT
209.	JunB-N-6	CATACAAAAAAGT
210.	JunB-N-7	CATACAAAAAAG
211.	JunB-N-8	GAAAAAAACATAC
212.	JunB-N-9	CAGAAAAAAACATAC
213.	JunB-N-10	CAGAAAAAAACAT
214.	JunB-N-11	TTCAATATGAATCG
215.	JunB-N-12	TATTCAATATGAATCG
216.	JunB-N-13	TATTCAATATGAATC
217.	JunB-N-14	TATTCAATATGAAT
218.	JunB-N-15	TATATTCAATATGAA
219.	JunB-N-16	TTATATTCAATATGA
220.	JunB-N-17	TATTATATTCAATATGA
221.	JunB-N-18	TTATATTCAATATG
222.	JunB-N-19	TATTATATTCAATATG
223.	JunB-N-20	ATTATATTCAATAT
224.	JunB-N-21	TATTATATTCAATAT
225.	JunB-N-22	ATATATTATATTCAATAT
226.	JunB-N-23	AAATATATTATATTCAATAT
227.	JunB-N-24	TATTATATTCAATA
228.	JunB-N-25	ATATATTATATTCAATA
229.	JunB-N-26	CAATATATTATATTCAATA
230.	JunB-N-27	TATATTATATTCAAT
231.	JunB-N-28	AATATATTATATTCAAT
232.	JunB-N-29	TATATTATATTCAA
233.	JunB-N-30	CAATATATTATATTCAA
234.	JunB-N-31	CAATATATTATATTCA
235.	JunB-N-32	CAATATATTATATTTC
236.	JunB-N-33	CACAAATATATTATATTC
237.	JunB-N-34	AAATATATTATATT
238.	JunB-N-35	CAATATATTATATT
239.	JunB-N-36	CAATATATTATAT
240.	JunB-N-37	CACAAATATATTATAT
241.	JunB-N-38	CACAAATATATTAT
242.	JunB-N-39	TACACAAATATATTAT
243.	JunB-N-40	TACACAAATATATTA
244.	JunB-N-41	TAAATACACAAATATATT
245.	JunB-N-42	AATACACAAATATA
246.	JunB-N-43	GTTAAATACACAAATA
247.	JunB-N-44	TGTTAAATACACAA
248.	JunB-N-45	TTTAGAGACTAAGT
249.	JunB-N-46	ATAAACTCTTTAGA
250.	JunB-N-47	TAAAAATAAACTCTTTAG
251.	JunB-N-48	TAAAAATAAACTCTTTA
252.	JunB-N-49	TTAAATAAACTCTTT
253.	JunB-N-50	CTTAAATAAACTC
254.	JunB-N-51	TAAAAAGAACAACAA
255.	JunB-N-52	TAAAAAGAACAAC
256.	JunB-N-53	CAATAAAAAAGAACAA
257.	JunB-N-54	TCAATAAAAAAGAAC
258.	JunB-N-55	TCAATAAAAAAGAAC
259.	JunB-N-56	TTCAATAAAAAAGAA
260.	JunB-N-57	TAGATTCAATAAAAAAGA

Fig. 3 - 4

7 / 36

261.	JunB-T-1	TGGCGCGGGCGGGTAGC
262.	JunB-T-2	GGGCTGGCGCGGGCGGGTAG
263.	JunB-T-3	TCGGGGGCTGGCGCGGGCGGG
264.	JunB-T-4	TGGGTGCCTGGTCGCGCGTTCTCGGG
265.	JunB-T-5	AGGGTCCCTGCGGGGCGG
266.	JunB-T-6	GGGAGGGTCCCTGCGGGG
267.	JunB-T-7	GGGAGGGTCCCTGCGG
268.	JunB-T-8	TGGGCCGGGTCCGC
269.	JunB-T-9	TCCCGGGGGTGTAG
270.	JunB-T-10	AGTACTGTCCCGGGGGTGT
271.	JunB-T-11	GGGACACGTTGGGGGGTG
272.	JunB-T-12	GCCGGGGGCCCCCGGTAGC
273.	JunB-T-13	CGGGCCCAGCCGGGGC
274.	JunB-T-14	CGGGCCCAGCCGGG
275.	JunB-T-15	GGGAGGTGGCTCCGGGCGG
276.	JunB-T-16	AGGGCGGCGCGTGTGGGA
277.	JunB-T-17	GGGTGGCCACCGCGAAGGG
278.	JunB-T-18	AGGGGCAGGGGACGT
279.	JunB-T-19	TAAAGGGGCAGGGGACGT
280.	JunB-T-20	AGGGGGTGTCCGTAAAGGGG
281.	JunD-T-1	GGGGACGCGAACGTGCCGCGG
282.	JunD-T-2	CGGGGAACAAGCGGCCCGGG
283.	JunD-T-3	GGCCGTCGGGGGCG
284.	JunD-T-4	GCGGCCGTCCGGGGC
285.	JunD-T-5	AGGGGGGTAGGAGGCGGG
286.	JunD-T-6	GCGCTGGGGGCGCC
287.	JunD-T-7	GGCCGTCGGGGGGT
288.	JunD-T-8	GGGGAGGCCAGCTTC
289.	JunD-T-9	GGCCGCCACCTTGGGG
290.	JunD-T-10	GCGGCCGCGCGCGGGG
291.	JunD-T-11	GGGCGCGGCCGCGCGGGG
292.	JunD-T-12	GGGGTGGCGGGCGGG
293.	JunD-T-13	GGGGGTGGCGGGCGG
294.	JunD-T-14	TGGGGCAGCAGCTGGCAG
295.	JunD-T-15	CGGGGCGCCACGACACC
296.	JunD-T-16	CGGGGCGCCACGACAC
297.	JunD-T-17	GGGCCGACCCTCTCCAAGTCCGGGG
298.	ErbB-2-1	GCAGCAGTCAGTGG
299.	ErbB-2-2	CCATTGTCTAGCACGG
300.	ErbB-2-3	GGTCTCCATTGTCTAGC
301.	ErbB-2-4	GGTGGTATTGTTCAGC
302.	ErbB-2-5	GCTGGATCAAGACCC
303.	ErbB-2-6	CCACAAAATCGTGTCC
304.	ErbB-2-7	CCTTCCACAAAATCGTGTCC
305.	ErbB-2-8	GGTTGTTCTTGTGG
306.	ErbB-2-9	CCTCTTGGTTGTGC
307.	ErbB-2-10	CCAGAGTCTCAAACACTTGG
308.	ErbB-2-11	GGTAACCTGTGATCTCTCC
309.	ErbB-2-12	CCTGCAGTACTCGG
310.	ErbB-2-13	GGCATTACATACTCC
311.	ErbB-2-14	GCAAACAGTGCCCTGGC
312.	ErbB-2-15	CGCATCGTGTACTTCCG
313.	ErbB-2-16	GCACGTTCCGAGCG
314.	ErbB-2-17	GGTACCAGATACTCC
315.	ErbB-2-18	CCAGTGGAGACCTGG
316.	ErbB-2-19	CCTGAGGACACATCAGG
317.	ErbB-2-20	CCTCACTTGGTTGTGAGC
318.	ErbB-2-21	GGAAGATGTCCTTCC
319.	ErbB-2-22	GCACACTGCTCATGGC
320.	ErbB-2-23	GCTGTCACCTCTTGG
321.	ErbB-2-24	CCTCTGCTGTCAAC
322.	ErbB-2-25	CCACACATCACTCTGG
323.	ErbB-2-26	CCTCCTCTTCAGAGG

Fig. 3 - 5

8 / 36

324.	ErbB-2-27	CCTTCTGGTTCACACTGG
325.	ErbB-2-28	CATGGTGCTCACTGCG
326.	ErbB-2-29	CTTGGTTGTGAGCG
327.	ErbB-2-30	GGACAGGCAGTCAC
328.	ErbB-2-31	GTCACCTCTTGGTTGTGC
329.	ErbB-2-32	CCAGAGTCTCAAACAC
330.	ErbB-2-33	CACATACTCCCTGG
331.	ErbB-2-34	GACCAGCACGTTCCG
332.	ErbB-2-35	GTGGTGTCTATCAGTG
333.	ErbB-2-36	CCCTGGTAGAGGTG
334.	ErbB-2-37	CTCAAACACTTGGAGC
335.	ErbB-2-38	CACACATCACTCTGGTGG
336.	ErbB-2-39	GCACAGACAGTGCGC
337.	ErbB-2-40	CATGGCAGCAGTCAG
338.	ErbB-2-41	CTGCTCATGGCAGCAG
339.	ErbB-2-42	CATCTGGAAACTTCCAGATG
340.	ErbB-2-43	CTGGAAACTTCCAG
341.	ErbB-2-44	CATAACTCCACATCACTC
342.	ErbB-2-45	CACCATAACTCCACATC
343.	ErbB-2-46	CTGGTGGGTGAACC
344.	ErbB-2-47	CGGATTACTTGCAGG
345.	ErbB-2-48	CGCTAGGTGTCAGCG
346.	ErbB-2-49	GCCATCACGTATGC
347.	ErbB-2-50	GCATACACCAGTTCAGC
348.	ErbB-2-51	CCATCAAATACATCGG
349.	ErbB-2-52	CCAGCAGAAGTCAGG
350.	ErbB-2-53	GCTTCATGTCTGTGC
351.	ErbB-2-54	GGTGAGTTCAGGTTTCC
352.	ErbB-2-55	CCACAAAATCGTGTCTCGG
353.	ErbB-2-56	CCCTTACACATCGG
354.	ErbB-2-57	GCAGCTCACAGATGC
355.	ErbB-2-58	GCACTGGTAACTGC
356.	ErbB-2-59	CCTGGATATTGGCACTGG
357.	ErbB-2-60	CCAGCAAACCTCTGG
358.	ErbB-2-61	GCAGAAATGCCAGGC
359.	ErbB-2-62	CCATTGTGCAGAATTCCG
360.	ErbB-2-63	CCCTGCAGTACTCGG
361.	ErbB-2-64	GGCATTCACATACTCCC
362.	ErbB-2-65	GGTCAGGTTTCACACU
363.	ErbB-2-66	CCAGGTCCACACAGG
364.	ErbB-2-67	CCTTGTTCATCCAGG
365.	ErbB-2-68	GGATCCCAAAGACC
366.	ErbB-2-69	CCTCAACACTTTGATGG
367.	ErbB-2-70	GCTGTGTCACCAGC
368.	ErbB-2-71	GGTCTAAGAGGCAGCC
369.	ErbB-2-72	GGCAATCTGCATACACC
370.	ErbB-2-73	CCTGTGTACGAGCC
371.	ErbB-2-74	CCATCCACTTGATGG
372.	ErbB-2-75	CCCACACAGTCACACC
373.	ErbB-2-76	CCATCGTAAGGTTTGG
374.	ErbB-2-77	CCTTTTCCAGCAGG
375.	ErbB-2-78	GGAGAATTTCAGACACC
376.	ErbB-2-79	CCAAGTCCCTCATTTCTGG
377.	ErbB-2-80	CCATCAGTCTCAGAGG
378.	ErbB-2-81	CCTTTGAAGGTGCTGG
379.	ErbB-2-82	GGCATGGCAGGTTCC
380.	ErbB-2-83	CCTGGCATGGCAGG
381.	ErbB-2-N-1	AGATGTATAGGTAA
382.	ErbB-2-N-2	ATTTTCACATTCTC
383.	ErbB-2-N-3	AATTTTCACATTCTC
384.	ErbB-2-N-4	AATTTTCACATTCT
385.	ErbB-2-N-5	GAATTTTCACATT
386.	ErbB-2-N-6	GGATTTTCACATT
387.	ErbB-2-N-7	AGATTTCTTTGTTG
388.	ErbB-2-N-8	AAGATTTCCTTTGTTG
389.	ErbB-2-N-9	AAGATTTCCTTTGTT

Fig. 3 - 6

9 / 36

390.	ErbB-2-N-10	TAAGATTTCCTTGT
391.	ErbB-2-N-11	CTAAGATTTCCTTGT
392.	ErbB-2-N-12	TAAGATTTCCTTGT
393.	ErbB-2-N-13	CTAAGATTTCCTTGT
394.	ErbB-2-N-14	CTAAGATTTCCTTGT
395.	ErbB-2-N-15	TCTAAGATTTCCTT
396.	ErbB-2-N-16	GTCTAAGATTTCCTT
397.	ErbB-2-N-17	GTCTAAGATTTCCTT
398.	ErbB-2-N-18	TTCGTCTAAGATT
399.	ErbB-2-N-19	ATTTTGACATGGTT
400.	ErbB-2-N-20	AATTTTGACATGGTT
401.	ErbB-2-N-21	AATTTTGACATGGT
402.	ErbB-2-N-21	TAATTTTGACATGGT
403.	ErbB-2-N-23	TAATTTTGACATGG
404.	ErbB-2-N-24	GTAATTTTGACATG
405.	ErbB-2-N-25	TGTAATTTTGACATG
406.	ErbB-2-N-26	TGTAATTTTGACAT
407.	ErbB-2-N-27	TCTGTAATTTTGACAT
408.	ErbB-2-N-28	CTGTAATTTTGACA
409.	ErbB-2-N-29	TCTGTAATTTTGACA
410.	ErbB-2-N-30	TCTGTAATTTTGAC
411.	ErbB-2-N-31	GTCTGTAATTTTGA
412.	ErbB-2-N-32	AAGTCTGTAATTTGA
413.	ErbB-2-N-33	AGTCTGTAATTTTG
414.	ErbB-2-N-34	AAGTCTGTAATTTTG
415.	ErbB-2-N-35	AAGTCTGTAATTTT
416.	ErbB-2-N-36	GAACTCTGTAATTTT
417.	ErbB-2-N-37	GAACTCTGTAATTT
418.	ErbB-2-N-38	ATGTAGACATCAAT
419.	ErbB-2-N-39	ATCATCCAACATTT
420.	ErbB-2-N-40	AATCATCCAACATTT
421.	ErbB-2-N-41	AATCATCCAACATTT
422.	ErbB-2-N-42	ACCATCAAATACAT
423.	ErbB-2-N-43	AAAAACGCTCTTGA
424.	ErbB-2-N-44	TTTTGTTCTTAGACA
425.	ErbB-2-N-45	TTTTGTTCTTAGAC
426.	ErbB-2-N-46	TAAACAGAAAAGCA
427.	ErbB-2-N-47	ACTAAACAGAAAAG
428.	ErbB-2-N-48	AAACTAAACAGAAAAG
429.	ErbB-2-N-49	AACTAAACAGAAAA
430.	ErbB-2-N-50	AACTAAACAGAAAA
431.	ErbB-2-N-51	AACTAAACAGAAA
432.	ErbB-2-N-52	TAAAAACTAAACAGAAA
433.	ErbB-2-N-53	AAAACTAAACAGAA
434.	ErbB-2-N-54	GTA AAAACTAAACAGAA
435.	ErbB-2-N-55	AAAAACTAAACAGA
436.	ErbB-2-N-56	TAAAAACTAAACAGA
437.	ErbB-2-N-57	TAAAAACTAAACAG
438.	ErbB-2-N-58	GTA AAAACTAAACA
439.	ErbB-2-N-59	AAAAAGTAAAAACTAAACA
440.	ErbB-2-N-60	AGTAAAAACTAAAC
441.	ErbB-2-N-61	AAAAAAAGTAAAAACTAAAC
442.	ErbB-2-N-62	AAGTAAAAACTAAA
443.	ErbB-2-N-63	AAAAAAAGTAAAAACTAAA
444.	ErbB-2-N-64	AAAGTAAAAACTAA
445.	ErbB-2-N-65	AAAGTAAAAACTA
446.	ErbB-2-N-66	AAAAAAAGTAAAAACTA
447.	ErbB-2-N-67	AAAAAGTAAAAACT
448.	ErbB-2-N-68	AAAAAAAGTAAAAACT
449.	ErbB-2-N-69	AAAAAAAGTAAAAAC
450.	ErbB-2-N-70	CAAAAAAGTAAAAAC
451.	ErbB-2-N-71	AAAAAAAGTAAAAA
452.	ErbB-2-N-72	CAAAAAAGTAAAA
453.	ErbB-2-N-73	AACAAAAACAAAAAAGTAAA
454.	ErbB-2-N-74	AAACAAAAAAGTA
455.	ErbB-2-N-75	CAAAACAAAAAAGTA
456.	ErbB-2-N-76	CAAAACAAAAAAGT

Fig. 3 - 7

10 / 36

457.	ErbB-2-N-77	CAAAACAAAAAAG
458.	ErbB-2-N-78	CTTTAAAAAACAAAAC
459.	ErbB-2-N-79	TCTTTAAAAAACAAA
460.	ErbB-2-N-80	GTCTTTAAAAAACAAA
461.	ErbB-2-N-81	GTCTTTAAAAAACAA
462.	ErbB-2-N-82	GTCTTTAAAAAAC
463.	ErbB-2-N-83	TTTATTTCTCTTT
464.	ErbB-2-N-84	TCTTTATTTCTCT
465.	ErbB-2-N-85	TATTTGCAAATGGA
466.	ErbB-2-N-86	TATATTGCAAATGG
467.	ErbB-2-N-87	TATATTGCAAATG
468.	ErbB-2-N-88	CAAAATATATTTGCAAATG
469.	ErbB-2-N-89	CAAAATATATTTGCAAAT
470.	ErbB-2-N-90	CAAAATATATTTGCA
471.	ErbB-2-N-91	CAAAATATATTTGC
472.	ErbB-2-N-92	TTCCAAATATATTTG
473.	ErbB-2-N-93	TTTTCCAAATATATTT
474.	ErbB-2-N-94	GTTTTCCAAATATATT
475.	ErbB-2-N-95	GTTTTCCAAATAT
476.	c-fos-1	GGTTAGGCAAAGCC
477.	c-fos-2	CCGAGAACATCATCGTGG
478.	c-fos-3	CCGAGAACATCATCGTG
479.	c-fos-4	CCGAGAACATCATCG
480.	c-fos-5	CGTAGTCTGCGTTGAAGC
481.	c-fos-6	CCATGCTGGAGAAGG
482.	c-fos-7	CCGTGCGAAGTCC
483.	c-fos-8	GGAATGAAGTTGGC
484.	c-fos-8	TGACCGTGGGAATG
485.	c-fos-10	TGGCAGTGACCGTG
486.	c-fos-11	AGATGGCAGTGACC
487.	c-fos-12	CGAGATGGCAGTGACC
488.	c-fos-13	CCAGCCACTGCAGG
489.	c-fos-14	GCACCAGCCACTGC
490.	c-fos-15	CCCTGGAGTAAGCC
491.	c-fos-16	GGAGATAACTGTTCCACC
492.	c-fos-17	GGAGATAACTGTTCC
493.	c-fos-18	CTTCTAGTTGGTCTG
494.	c-fos-19	CATCTCTAGTTGG
495.	c-fos-20	TCTCATCTTCTAGTTGG
496.	c-fos-21	CTGCAAAGCAGACTTCTC
497.	c-fos-22	CCTTCAGCAGGTTGG
498.	c-fos-23	CCAGGTCATCAGG
499.	c-fos-24	CCAGTCAGATCAAGG
500.	c-fos-25	GGTGAAGGCCTCCTC
501.	c-fos-26	CAGGGTGAAGGCCTC
502.	c-fos-27	CCTGGATGATGCTGG
503.	c-fos-28	CCACTGTGCAGAGG
504.	c-fos-29	GGAGTACAGGTGACC
505.	c-fos-30	GCTCATTGCTGCTGC
506.	c-fos-31	GGAAGGCTCATTGCTGC
507.	c-fos-N-1	TTTTCTCTTCTTCT
508.	c-fos-N-2	ATCTTATTCCTTTC
509.	c-fos-N-3	CATCTTATTCCTTT
510.	c-fos-N-4	TAGTTTTTCCTTCT
511.	c-fos-N-5	TCTAGTTTTTCCTT
512.	c-fos-N-6	AACTCTAGTTTTTC
513.	c-fos-N-7	GAACTCTAGTTTTT
514.	c-fos-N-8	TGAACTCTAGTTTTT
515.	c-fos-N-9	ATGAACTCTAGTTTTT
516.	c-fos-N-10	TGAACTCTAGTTTTT
517.	c-fos-N-11	ATGAACTCTAGTTTTT
518.	c-fos-N-12	ATGAACTCTAGTTTT
519.	TGF-β2-1	GCACACAGTAGTGC

11 / 36

520.	TGF-82-2	GCAGGATCAGAAAAGC
521.	TGF-82-3	GCAGGTAGACAGGC
522.	TGF-82-4	GCTTGCTCAGGATCTGC
523.	TGF-82-5	GCAAGTCCCTGGTGC
524.	TGF-82-6	CCTGGAGCAAGTCC
525.	TGF-82-7	CGTAGTACTCTTCGTCG
526.	TGF-82-8	CGTAGTACTCTTCG
527.	TGF-82-9	GTAAACCTCCTTGG
528.	TGF-82-10	GTCTATTTTGTAAACCTCC
529.	TGF-82-11	GCATGTCTATTTTGTAAACC
530.	TGF-82-12	GGCATCAAGGTACCC
531.	TGF-82-13	GGCATCAAGGTACC
532.	TGF-82-14	GCTTTACCAAATTGGAAGC
533.	TGF-82-15	GAGAATCTGATATAGCTC
534.	TGF-82-16	GGAGATGTTAAATCTTTGG
535.	TGF-82-17	GCTGTGATGTAGC
536.	TGF-82-18	CCAGGTTCTGTCTTTATG
537.	TGF-82-19	CAGCAGGGACAGTG
538.	TGF-82-20	CTTGCTTCTAGTTCTTCAC
539.	TGF-82-21	GCCATCAATACCTGC
540.	TGF-82-22	GGTGCCATCAATACC
541.	TGF-82-23	CCACTGGTATATGTGG
542.	TGF-82-24	GGACTTTATAGTTTCTG
543.	TGF-82-25	CTCAAGTCTGTAGGAG
544.	TGF-82-26	GGTCTGTGTGACTC
545.	TGF-82-27	CAATTATCTGCACATTTT
546.	TGF-82-28	GCAGCAATTATCCTGC
547.	TGF-82-29	GGCAGCAATTATCC
548.	TGF-82-30	GGTTGCTGTATCCATTTCC
549.	TGF-82-31	GCACAGAAAGTTGGC
550.	TGF-82-32	CCAGCACAGAAGTTGG
551.	TGF-82-33	GTGCTGAGTGTCTG
552.	TGF-82-34	CCTGCTGTGCTGAGTG
553.	TGF-82-35	GCTCAGGACCCTGC
554.	TGF-82-36	GCAGCAAGGAGAAGC
555.	TGF-82-37	CCAATGTAGTAGAGAATGG
556.	TGF-82-38	GCTGCATTTGCAAG
557.	TGF-82-N-1	AAAAAAGAAATCAA
558.	TGF-82-N-2	AAAAAAGAAATCAA
559.	TGF-82-N-3	AAAAAAGAAATCAA
560.	TGF-82-N-4	TAAAAAAGAAATCAA
561.	TGF-82-N-5	ATAAAAAAAGAAATCAA
562.	TGF-82-N-6	AATAAAAAAAGAAATCAA
563.	TGF-82-N-7	GAATAAAAAAAGAAAT
564.	TGF-82-N-8	AGAATAAAAAAAGAAAT
565.	TGF-82-N-9	CAGAATAAAAAA
566.	TGF-82-N-10	TCAGAATAAAAAA
567.	TGF-82-N-11	TTGTTTTTAAAGT
568.	TGF-82-N-12	AGTTGTTTTTAAAA
569.	TGF-82-N-13	AAGTTGTTTTTAAAA
570.	TGF-82-N-14	AAAGTTGTTTTTAAAA
571.	TGF-82-N-15	AAAAGTTGTTTTTAAAA
572.	TGF-82-N-16	AAAAAGTTGTTTTTAAAA
573.	TGF-82-N-17	AAAAAGTTGTTTTTAAAA
574.	TGF-82-N-18	AAAAAGTTGTTTTTAAAA
575.	TGF-82-N-19	AAAAAGTTGTTTTTAAAA
576.	TGF-82-N-20	TTTTTAAAAAAGTG
577.	TGF-82-N-21	TTTTTAAAAAAGTG
578.	TGF-82-N-22	ATTTTTTAAAAAAGTG
579.	TGF-82-N-23	CATTTTTTAAAAAAGT
580.	TGF-82-N-24	GCATTTTTTAAAAA
581.	TGF-82-N-25	TGCATTTTTTAAAAA
582.	TGF-82-N-26	AGCTTATTTTAAAT
583.	TGF-82-N-27	AAGCTTATTTTAAAT
584.	TGF-82-N-28	TAAGCTTATTTTAAAT
585.	TGF-82-N-29	TGTAATTATTAGAT

Fig. 3 - 9

12 / 36

586.	TGF-E2-N-30	ATGTAATTATTAGAT
587.	TGF-E2-N-31	TGATGTAATTATTA
588.	TGF-E2-N-32	ATGATGTAATTATTA
589.	TGF-E2-N-33	ATGGTATTATATAA
590.	TGF-E2-N-34	TATGGTATTATATAA
591.	TGF-E2-N-35	TTATGGTATTATATAA
592.	TGF-E2-N-36	TTTATGGTATTATATAA
593.	TGF-E2-N-37	ATTTATGGTATTATATAA
594.	TGF-E2-N-38	AATCATATTAGAAA
595.	TGF-E2-N-39	TTACAATCATATTA
596.	TGF-E2-N-40	TTTACAATCATATTA
597.	rb-1	GGCATGACGCCTTTCC
598.	rb-2	GCATGACGCCTTTC
599.	rb-3	GCCTGACGAGAGGC
600.	rb-4	CTCAAGCCTGACGAG
601.	rb-5	CCACAGTTCCTTTTTC
602.	rb-6	GCTGCAATAAAGATACAG
603.	rb-7	GCTGCAATAAAGATAC
604.	rb-8	GGACACTGATTTCTATG
605.	rb-9	GCATTATCAACTTTGG
606.	rb-10	ACTTTTAGCACC AATG
607.	rb-11	CCAAGAACTTTTAGCACC
608.	rb-12	CCAGATCATCTTCC
609.	rb-13	AGTCAAGGACACATAG
610.	rb-14	TCTTTGAGCAACATGG
611.	rb-15	GGGTATAACAGCTG
612.	rb-16	GAGGTGAACCAATTAATGG
613.	rb-17	TCTTCGTATCGTTAG
614.	rb-18	TGTTGGATAGTGTTC
615.	rb-19	GTTGATCACTTGCTG
616.	rb-20	GGATTCCATTACTCG
617.	rb-21	GACATATGAAAAATGTTGTC
618.	rb-22	GCCAATAAAGACATATG
619.	rb-23	CCAGAAATCAAGATTCTG
620.	rb-24	CTGTTCCAGAATCAAG
621.	rb-25	GACAAATCTGTTCCAGAATC
622.	rb-26	GGAAAGACAAATCTGTTCC
623.	rb-27	GATTAAAGAGGACAGC
624.	rb-28	GGAAAGATTAAAGAGG
625.	rb-29	GCAGTGTGATTATTCTGG
626.	rb-30	GGAGAAAGATACATATCTG
627.	rb-31	GGAGATCTTACAGG
628.	rb-32	GCATTTGCAGTAGAATTTAC
629.	rb-33	CAGTGAAAGAGAGG
630.	rb-34	GCTAGCCGATACAC
631.	rb-35	GGAAGATCCTTGTATGC
632.	rb-36	GCATGAGGAAGATCC
633.	rb-37	GGAGTCATTTTGTG
634.	rb-38	CCAATTGATACTAAGATTTC
635.	rb-39	TCTTTTGAGCACACG
636.	rb-40	CCTTCAGCACTTCTTTTG
637.	rb-41	GGTTGCTTCCTTCAGC
638.	rb-42	CAGTGGTTTAGGAG
639.	rb-43	CCTGAGATCCTCATTTC
640.	rb-44	CCAAGGTCTGAGATCC
641.	rb-45	GGTGACACAGTGTCC
642.	rb-N-1	TATCTTTAATTTC
643.	rb-N-2	TCTTTTGAATATAA
644.	rb-N-3	TTCTTTTGAATATAA
645.	rb-N-4	TTTTCTTTTGAATATAA
646.	rb-N-5	TTTTCTTTTGAATATAA
647.	rb-N-6	TTTTCTTTTGAATATAA
648.	rb-N-7	ATTTCTATGTTTTT
649.	rb-N-8	TTAAAGAATTTATG
650.	rb-N-9	GTTAAAGAATTTAT

Fig. 3 - 10

13 / 36

651.	rb-N-10	AGTTAAAGAATTAT
652.	rb-N-11	AAGTTAAAGAATTAT
653.	rb-N-12	TAAGTTAAAGAATTAT
654.	rb-N-13	TTTAGTAAGTTAAA
655.	rb-N-14	TTTTAGTAAGTTAAA
656.	rb-N-15	ATTTCTTTTAGTAA
657.	rb-N-16	AATTTCTTTTAGTAA
658.	rb-N-17	ATCAATTTCTTTTA
659.	rb-N-18	TATCAATTTCTTTTA
660.	rb-N-19	AATATATAAGTTCA
661.	rb-N-20	AAATATATAAGTTCA
662.	rb-N-21	CAAATATATAAGTT
663.	rb-N-22	TCAAATATATAAGTT
664.	rb-N-23	TGTCAAATATATAA
665.	rb-N-24	AATTTATTTTCAGTA
666.	rb-N-25	AATAAAAAATGTGAT
667.	rb-N-26	TAATAAAAAATGTGAT
668.	rb-N-27	TAGCTAATAAAAAAT
669.	rb-N-28	TTAGCTAATAAAAAAT
670.	rb-N-29	TTTAGCTAATAAAAAAT
671.	rb-N-30	AATAAAATAGTCAA
672.	rb-N-31	TAATAAAATAGTCAA
673.	rb-N-32	TTAATAAAATAGTCAA
674.	rb-N-33	TTTAATAAAATAGTCAA
675.	rb-N-34	GTTTAATAAAATAGT
676.	rb-N-35	AGTTTAATAAAATAGT
677.	rb-N-36	GAGTTTAATAAAATA
678.	rb-N-37	AGAGTTTAATAAAATA
679.	rb-N-38	AATAATTTCTGTAT
680.	rb-N-39	TATATTACATTTCAT
681.	rb-N-40	ATCTATATTACATT
682.	rb-N-41	ATAAACATTTTTTCA
683.	rb-N-42	AAATAAACATTTTTTCA
684.	rb-N-43	AAATAAACATTTTTTCA
685.	rb-N-44	GAAATAAACATTTTTT
686.	rb-N-45	TGAAATAAACATTTTTT
687.	rb-N-46	TTGAAATAAACATTTTTT
688.	rb-N-47	TTTGAAATAAACATTTTTT
689.	rb-N-48	TTTTGAAATAAACATTTTTT
690.	rb-N-49	TTTTTGAAATAAACATTTTTT
691.	rb-N-50	ATTTTTGAAATAAACATTTTTT
692.	rb-N-51	AATTTTTGAAATAAACATT
693.	rb-N-52	AAATTTTTGAAATAAACATT
694.	rb-N-53	AAAATTTTTGAAATAAACAT
695.	rb-N-54	TAAAATTTTTGAAATAAACAT
696.	rb-N-55	ATAAAATTTTTGAAATAAAC
697.	rb-N-56	TATAAAATTTTTGAAATAAAC
698.	rb-N-57	GTATAAAATTTTTGAAAT
699.	rb-N-58	GGTATAAAATTTTTT
700.	rb-N-59	AGGTATAAAATTTTTT
701.	rb-N-60	AAGGTATAAAATTTTTT
702.	rb-N-61	AAAGGTATAAAATTTTTT
703.	rb-N-62	AAAAGGTATAAAATTTTTT
704.	rb-N-63	TAAAAGGTATAAAATTTTTT
705.	rb-N-64	ATAAAAGGTATAAAATTTTTT
706.	rb-N-65	TTAGAAAGATTTTTT
707.	rb-N-66	AAGATAAAATTTCTT
708.	rb-N-67	TAAGATAAAATTTCTT
709.	rb-N-68	TTAAGATAAAATTTCTT
710.	rb-N-69	TTTAAGATAAAATTTCTT
711.	rb-N-70	TTTTAAGATAAAATTTCTT
712.	rb-N-71	TTTTTAAGATAAAATTTCTT
713.	rb-N-72	ATTTTTAAGATAAAATTTCTT
714.	rb-N-73	TATTTTTAAGATAAAATTTCTT
715.	rb-N-74	TTATTTTTAAGATAAAATT
716.	rb-N-75	TTTATTTTTAAGATAAAATT
717.	rb-N-76	CTTTATTTTTAAGATAAAAT

Fig. 3 - 11

14 / 36

718.	rb-N-77	TCTTTATTTTAAAGATAAAT
719.	rb-N-78	ATCTTTATTTTAAAGATAAA
720.	rb-N-79	ATCTTTATTTTAA
721.	rb-N-80	GATCTTTATTTTAA
722.	rb-N-81	AGATCTTTATTTTAA
723.	rb-N-82	TAGATCTTTATTTTAA
724.	rb-N-83	AATCATCATTAATT
725.	rb-N-84	AAATCATCATTAATT
726.	rb-N-85	AAAATCATCATTAATT
727.	rb-N-86	TAAAATCATCATTAATT
728.	rb-N-87	TTAAAATCATCATTAATT
729.	rb-N-88	TTTAAAATCATCATTAATT
730.	rb-N-89	ATTTAAAATCATCATTAATT
731.	rb-N-90	AAATTTAAAATCATCATTA
732.	rb-N-91	GAATTTAAAATCAT
733.	rb-N-92	TGAATTTAAAATCAT
734.	rb-N-93	TTAAAATAGGAAAT
735.	rb-N-94	AATTTCTCTTAA
736.	rb-N-95	AAATTTCTCTTAA
737.	rb-N-96	TAAAATTTTGAATG
738.	rb-N-97	CTAAAATTTTGAAT
739.	rb-N-98	TTTGCTAAAATTTT
740.	rb-N-99	ATATGAAAAATGTT
741.	rb-N-100	TTTTAAATTAAGCA
742.	rb-N-101	TTGTAAAAATCAAA
743.	rb-N-102	TTTGTAAAAATCAAA
744.	rb-N-103	TTTGATAAACTTT
745.	rb-N-104	ATGTTTATCATTT
746.	rb-N-105	AATGTTTATCATTT
747.	rb-N-106	AAATGTTTATCATTT
748.	rb-N-107	TAAATGTTTATCATTT
749.	rb-N-108	TCTAAATGTTTAT
750.	rb-N-109	TTCTAAATGTTTAT
751.	rb-N-110	TAAGATCAAATAAA
752.	rb-N-111	ATAAGATCAAATAAA
753.	rb-N-112	AATAAGATCAAATAAA
754.	rb-N-113	TAATAAGATCAAATAAA
755.	rb-N-114	TTAATAAGATCAAATAAA
756.	rb-N-115	TTTAAATAAGATCAAATAAA
757.	rb-N-116	TTGTTAATAAGAT
758.	rb-N-117	ATTGTTAATAAGAT
759.	rb-N-118	TGATTGTTAATAA
760.	rb-N-119	TTGATTGTTAATAA
761.	rb-N-120	TTTGATTGTTAATAA
762.	rb-N-121	TTTTATAAAACAGT
763.	rb-N-122	TTTTTATAAAACAGT
764.	rb-N-123	TTTTTTATAAAACAGT
765.	rb-N-124	CTTTTTATAAAACA
766.	rb-N-125	ACTTTTTATAAAACA
767.	rb-N-126	CACTTTTATAAAAA
768.	rb-N-127	ACACTTTTTATAAAAA
769.	rb-N-128	TACACTTTTTATAAAAA
770.	rb-N-129	ATACACTTTTTATAAAAA
771.	rb-N-130	ATTTTGAATTTAAG
772.	rb-N-131	GATTTTGAATTTAA
773.	rb-N-132	TGATTTTGAATTTAA
774.	rb-N-133	ATGATTTTGAATTTAA
775.	rb-N-134	AATGATTTTGAATTTAA
776.	rb-N-135	ATAATAGAATCATA
777.	rb-N-136	TATAATAGAATCATA
778.	rb-N-137	TATAATAGAATCAT
779.	rb-N-138	TACTATAATAGAAT
780.	rb-N-139	ATACTATAATAGAAT
781.	rb-N-140	AATACTATAATAGAAT
782.	rb-N-141	AGAATACTATAATA
783.	rb-N-142	TAGAATACTATAATA
784.	rb-N-143	ATAGAATACTATAATA

Fig. 3 - 12

15 / 36

785.	rb-N-144	TATAGAATACTATAATA
786.	rb-N-145	TTATAGAATACTATAATA
787.	rb-N-146	AATATTTGTTTTCA
788.	rb-N-147	AAATATTTGTTTTCA
789.	rb-N-148	AAAATATTTGTTTTCA
790.	rb-N-149	CAAAATATTTGTTTT
791.	rb-N-150	AAATTTTATATGGA
792.	rb-N-151	TGAAATTTTATATG
793.	rb-N-152	CTGAAATTTTATAT
794.	rb-N-153	TCTGAAATTTTATAT
795.	rb-N-154	TTCTGAAATTTTATAT
796.	rb-N-155	ATCTGATTTATTTT
797.	rb-N-156	AAGATATTAAATGT
798.	rb-N-157	TGAAGATATTAAAT
799.	rb-N-158	ATAAATAACAATGA
800.	rb-N-159	TATAAATAACAATGA
801.	rb-N-160	GTATAAATAACAAT
802.	rb-N-161	TGTATAAATAACAAT
803.	rb-N-162	TTGTATAAATAACAAT
804.	rb-N-163	TCTTGTATAAATAA
805.	rb-N-164	ATCTTGTATAAATAA
806.	rb-N-165	AATCTTGTATAAATAA
807.	rb-N-166	ACAACTTTTTTAAAT
808.	rb-N-167	TACAACTTTTTTAAAT
809.	rb-N-168	TACAACTTTTTTAAA
810.	rb-T-1	CGGGGGGTTTTGGGCGGCATG
811.	rb-T-2	TTTTCGGGGGGTTTTGGGCGGCA
812.	rb-T-3	TCGGGGGGTTTTGGGCGGC
813.	rb-T-4	GGTGGCGGCCGTTTTTCGGGGGGT
814.	rb-T-5	CCGGGGGTTCCGCGGCGGCAGCG
815.	rb-T-6	CGGGGGTTCCGCGGCGG
816.	rb-T-7	GGCGGCGGTGCGGGGGTTCCGC
817.	rb-T-8	GGAGGGGCGGCGGCGGCGGTG
818.	rb-T-9	GGGGGCGGCGGCGGCGG
819.	rb-T-10	GGGCGGCGGCGGCGG
820.	rb-T-11	AGGGGGCCTGGTGGAAG
821.	rb-T-12	TAGGGGGCCTGGTG
822.	rb-T-13	GTAGGGGGCCTGGT
823.	rb-T-14	GGGTTATGGGTGACAAAGTAGGGGGC
824.	rb-T-15	TCTTCAGGGGTGAAATATAGATGTTT
825.	rb-T-16	GGACTCTTCAGGGGTG

16 / 36

826	TCGGACTATA	CTGC
827	CAGTTCGGAC	TATACT
828	AAGCCTAAGA	CGCA
829	GCCCAAGTTC	AACA
830	TGAAAAGTCG	CGGT
831	GGTTAATTAA	GATGCCTC
832	TCTCTAAGAG	CGCA
833	ACGTGAGGTT	AGTTTG
834	CACGTGAGGT	TAGT
835	CATAGAACAG	TCCG
836	CAGTCATAGA	ACAGTC
837	CTTTGCAGTC	ATAGAACA
838	TGCAGTCATA	GAAC
839	GGTCGTTTCC	ATCT
840	CATAGAAGGT	CGTTTC
841	CGTCATAGAA	GGTC
842	CATCGTCATA	GAAGG
843	GGACGGGAGG	AACGAGGCGT TGAG
844	TAGCCATAAG	GTCC
845	GGTTACTGTA	GCCA
846	GGTTACTGTA	GCCA
847	AGTTCTTGGC	GCGGAGGT
848	AGGTGAGGAG	GTCCGAGT
849	TGGACTGGAT	TATCAG
850	GTGGTGGTGA	TGTGCCCG
851	TGTCACGTTC	TTGG
852	CTCATCTGTC	ACGT
853	CGAAGCCCTC	GGCGAACC
854	GCGTGTTCCTG	GCTGTGCAGT TCCG
855	CTGCCCCGTT	GACC
856	AGGTTTGCGT	AGAC
857	GGTTGAAGTT	GCTG
858	CTGGGTTGAA	GTTG
859	TGCTGCACGG	GCATCTGCTG
860	GGCACTGTCT	GAGGCTCCTC CTTCAGG
861	ACTCCATGTC	GATG
862	CTCTCCGCCT	TGATCC
863	GTTCCTCATG	CGCTTC
864	CTGAGCTTTC	AAGG
865	GCGATTCTCT	CCAGCTTCCT TTTTCG
866	CTGAGCTTTC	AAGGTTTTCA CTTTTTCCTC
867	TCCCTGAGCA	TGTT
868	TCTGTTTAAG	CTGTGC
869	CTTTCTGTTT	AAGCTGTG
870	GGTTCATGAC	TTTCTG
871	CGTGGTTCAT	GACT
872	ACTGTTAACG	TGGTTC
873	CCACTGTTAA	CGTG
874	CCCACTGTTA	ACGT
875	AGCATGAGTT	GGCA
876	GCGTTAGCAT	GAGT
877	GTTTGCAACT	GCTG
878	CAAAATGTTT	GCAACTGC

17 / 36

879	TCCATTTTAG	TGCACATC
880	CTGTTCCATT	TTAGTGCA
881	GTGTATGAGT	CGTC
882	CTGTGTATGA	GTCG
883	CGTAGCTGTG	TATG
884	TCGTGTAGAG	AGAG
885	AGTTTGTAGT	CGTGTAGA
886	GTTTGTAGTC	GTGTAG
887	AGTTTGTAGT	CGTG
888	GGAGTTTGTA	GTCG
889	TCAGGAGTTT	GTAGTC
890	GTTTCAGGAG	TTTGTAGT
891	TCGGTTTCAG	GAGT
892	TTGAGACTCC	GGTA
893	ACCAGAAAAG	TAGCTG
894	CCTGACCAGA	AAAG
895	ATTCAGGCGT	TCCA
896	GGTAAAAGTA	CTGTCC
897	GGGTAAAAGT	ACTGTC
898	GCACCTCCAC	CGCTGCCA
899	CTCCTGCTCC	TCGGTGAC
900	GCTTTGACAA	AGCC
901	CTTGTGCAGA	TCGT
902	TCATCTTGTG	CAGATC
903	GTTTATCTTG	TGCAGA
904	CGTGTTTCAT	CTTG
905	TCACGTGGTT	CATC
906	GGTTGGTGTA	AACG
907	TACGAGCTCC	CGGTCCCGAC
908	TAGCTGATGG	TGGT
909	TCCTTGAAGG	TGGA
910	TCCTCCATGT	TGATGG
911	CTTTGATGCG	CTCT
912	CTCCACTTTG	ATGC
913	GCTCCAGCTT	CCGCTTCCGG CACTTGGTGG
914	GGCCTTGAGC	GTCCTCACCT TGCTCTCCAG
915	TGACCTTCTG	TTTGAG
916	CATGACCTTC	TGTTTG
917	GTCATGACCT	TCTG
918	CGAGAACATC	ATCG
919	GTAGTCTGCG	TTGA
920	GCTGCAGCGG	GAGGATGACG
921	AGTAAGAGAG	GCTATC
922	GTAGTAAGAG	AGGC
923	GGTAGTAAGA	GAGG
924	GTGAGTG GTA	GTAAGA
925	GTCCGTGCAG	AAGTCCTG
926	GAATGAAGTT	GGCACT
927	GGAATGAAGT	TGGC
928	GGGAATGAAG	TTGG
929	GCTGCACCAG	CCACTGCAGG TCCGGACTGG
930	TCATGGTCTT	CACAAC
931	CAATGCTCTG	CGCTCGGCCT CCTGTGATGG

18 / 36

932 CTAGAGTTCC TCAC
933 GAGTACGCTA GAGT
934 GAAGAGTACG CTAG
935 CTGCTTCCCA CCCAGCCCC ACATTCCC
936 TTCATCCTCT GTACTGGGCT
937 GTTACGGATG TGCA
938 CAGTTACGGA TGTG
939 CCAGTTACGG ATGT
940 AGAGTCTGAG TTGG
941 GTGAGACTCA GAGT
942 TCTTAGGGTG AGAC
943 GAGAGTACTT CTTAGG
944 GGAAGAACT ATGAGAGT
945 CTTAGGGAAG AAACATG
946 CGGTAAGAAA CTTAGG
947 AGCATGCGGT AAGA
948 GTCTGAAAGC ATGC
949 AGAACAAAGA AGAGCC
950 CAAGAGAACA AAGAAGAG
951 CAGCAAGAGA ACAAG
952 TCCTCAGCAA GAGA
953 AGGTGTGACT TGCA
954 GAATAGGTGT GACTTG
955 CAGAATAGGT GTGACT
956 GCAGAATAGG TGTG
957 CAGTTGCAGA ATAGGT
958 GAAACCATT CTGACC
959 TGTGAAACCA TTTCTGAC
960 CACTGTGAAA CCATTTCT
961 CCACTGTGAA ACCA
962 AGAGTGGCT CCTGCAGCTT CCCTGCTTCC
963 CACCTCCATT CACCC
964 CAGTAAAAGT GTCTGC
965 CGACATTCAG TAAAAGTG
966 GACCGACATT CAGT
967 CTTCTGGAGA TAACTAGA
968 CATCTTATTC CTTCCCT
969 CAGCCATCTT ATTCTT
970 TGCAGCCATC TTATTC
971 GAGTGTATCA GTCAG
972 GGAGTGTATC AGTC
973 CTTGGAGTGT ATCAGT
974 ACAGAGTACC TACC
975 CCAACTTTCC CTTAAG
976 CCTTATGCTC AATCTC
977 GTCTTACTCA AGGG
978 ACAGTCTTAC TCAAGG
979 CATAAGACAC AGTCTTAC
980 GAAAGCATAA GACACAGT
981 GGAAAGCATA AGACAC
982 AGGGATAAAG GAAAGC
983 CCTGTATACA GAGG
984 TGTCTCCTGT ATACAG

19 / 36

985	CATCTTCTAG TTGGTC
986	CTCATCTTCT AGTTGG
987	CTTCTCATCT TCTAGTTG
988	CAAAGCAGAC TTCTCA
989	CTGCAAAGCA GACT
990	CTAGTTTTTC CTTCTCCT
991	TCTAGTTTTT CCTTCTCC
992	CAGGATGAAC TCTAGT
993	TCGTAGAAGG TCGT
994	AGGGTTACTG TAGC
995	GTAGTGGTGA TGTG
996	CGTCGTAGAA GGTC
997	TTTCGTGCAC ATCC
998	AGTTTGTAGT CGTGAAGA
999	CGAGAACATC ATGG
1000	GTAGTAGGAA AGGC
1001	GGTAGTAGGA AAGG
1002	GGAATGGTAG TAGG
1003	GGTCATTGAG AAGAG
1004	GCTAATGTTT TTGACC
1005	GCCAAGGTCCTCAT
1006	GGAGTCTATCTCCA
1007	CCAAAGAATCCTGACT
1008	CACATGCTTAGTGG
1009	CTCGTAAATGACCG
1010	AGGAATCTCGTAAATGAC
1011	CAGCAGCGATTTCAT
1012	GGAGATCATCAAAGGA
1013	CTCAGCAATGGTCA
1014	GATCTCGAACACCT
1015	CACAATCTCGATCTTTCT
1016	CCTTCTTAAAGATTGGCT
1017	CACATACCAACTGG
1018	AGCTTGATGTGAGG
1019	GAAATTGTAGCTTGATGT
1020	GCTTGAAGTTGTAGCT
1021	CTGCTTGAAGTTGTAG
1022	GACACAACCTCCTCT
1023	TCCTTTGATAGACACAAC
1024	CTCGTTTGATAGACAC
1025	GGTTAGCACACACT
1026	GGTAACGGTTAGCA
1027	CGTAACACATTTAGAAGC
1028	CTCATCCGTAAACAC
1029	CCGGTAAGTATTGTAGTT
1030	GGTGTATTTCTTGAC
1031	ACATACCAACTGGTGT
1032	GTCCCTATACGAAC
1033	TTCATGTCTG TGCC
1034	GTAGGTGAGT TCCA
1035	GTTGTGAGCG ATGA
1036	CATAGTTGTC CTCAAAGA
1037	GGCATAGTTG TCCT

20 / 36

1038	CATTGTCTAG	CACG
1039	CTCCATTGTC	TAGC
1040	GTATTGTTCA	GCGG
1041	TCAAGATCTC	TGTGAG
1042	CACAAAATCG	TGTCCT
1043	TCCTTCCACA	AAATCG
1044	GTGGAAGATG	TCCT
1045	TCTTGTGGAA	GATGTC
1046	TCTATCAGTG	TGAGAG
1047	GGTTGGTGTC	TATC
1048	ACATCGGAGA	ACAG
1049	CCTTACACAT	CGGA
1050	ACAATCCTCA	GAATCT
1051	GCTCTGACAA	TCCT
1052	TGGTTGAAGT	GGAG
1053	CTGTGGTTGA	AGTG
1054	GTTGTAGGTG	ACCA
1055	CTGTGTTGTA	GGTG
1056	GACTCAAACG	TGTC
1057	CATGGACTCA	AACG
1058	CGAATGTATA	CCGG
1059	CCGAATGTAT	ACCG
1060	GCCGAATGTA	TACC
1061	GTAGTTGTAG	GGAC
1062	TAGAAAGGTA	GTTGTAGG
1063	GTAGAAAGGT	AGTTGTAG
1064	CGTAGAAAGG	TAGTTG
1065	CCGTAGAAAG	GTAG
1066	GACCATAGCA	CACT
1067	GGATATTGGC	ACTG
1068	CCCTGATATT	GGCA
1069	GCTCCCAAAG	ATCT
1070	CCCATCAAAG	CTCT
1071	CAAACACTTG	GAGC
1072	GTCTCAAACA	CTTGGA
1073	GAGTCTCAAA	CACTTG
1074	GTAACCTGTG	ATCTCT
1075	GGTAACCTGT	GATC
1076	GTATAGGTAA	CCTGTG
1077	TGAGATGTAT	AGGTAACC
1078	TGCTGAGATG	TATAGG
1079	CCATGCTGAG	ATGT
1080	GGATTACTTG	CAGG
1081	TGTTATGGTG	GATGAG
1082	GGTGTATGG	TGGA
1083	GCAGTTGACA	CACT
1084	AGTACTCGGC	ATTC
1085	CATTACATA	CTCCCT
1086	TCCAAAACAG	GTCACT
1087	GGTCCTTATA	GTGG
1088	CAGAATGCCA	ACCA
1089	ACGAGAATGC	CAAC
1090	GATCCCAAAG	ACCA

21 / 36

1091	TCGCTTGATG	AGGA
1092	CATCGTGTAC	TTCC
1093	GCATCGTGTA	CTTC
1094	ACTGTGCCAA	AAGC
1095	CTTGTAAGCT	GTGC
1096	CCCTTGTAGA	CTGT
1097	TCAACACTTT	GATGGC
1098	CCCTCAACAC	TTTG
1099	GTGTTTTCCC	TCAACA
1100	GTATGCTTCG	TCTAAG
1101	CGTATGCTTC	GTCT
1102	CCATCACGTA	TGCT
1103	GCATAAGCTG	TGTC
1104	CATGGTCTAA	GAGG
1105	CAATCTGCAT	ACACCA
1106	GGCAATCTGC	ATAC
1107	CTGTCTCGTC	AATG
1108	CATAACTCCA	CACATC
1109	AGTCACACCA	TAATC
1110	ACAGTCACAC	CATAAC
1111	CCCCAAAAGT	CATC
1112	TCGTAAGGTT	TGGC
1113	GATCCCATCG	TAAG
1114	CAATGGTGCA	GATG
1115	GACATCAATG	GTGC
1116	GTAGACATCA	ATGGTG
1117	CATGATCATG	TAGACATC
1118	CCATGATCAT	GTAGAC
1119	CATTGACCA	TGATCATG
1120	CCAACATTTG	ACCATG
1121	TCATCCAACA	TTTGACCA
1122	GAGTCAATCA	TCCAACAT
1123	CAGAGTCAAT	CATCCA
1124	CCGACATTCA	GAGT
1125	GAATTCAGAC	ACCAAC
1126	GATGACCACA	AAGC
1127	CCATCAAATA	CATCGG
1128	TCACCATCAA	ATACATCG
1129	CAACGTAGCC	ATCA
1130	ACGTCTTTGA	CGAC
1131	CAAAAACGTC	TTTGACGA
1132	GGCAAAAACG	TCTTTG
1133	CAAAGGCAAA	AACGTC
1134	GTGTCAAGTA	CTCG
1135	GTAATAGAGG	TTGTCTG
1136	CCCAGTAATA	GAGG
1137	CATGGTGCTC	ACTG
1138	GTGCCTGTAC	GTAC
1139	TGCAGGTGGA	TAGT
1140	CATGTCGATA	GTCTTGCA
1141	GTGATAGTC	TTGC
1142	CCATGTCGAT	AGTC
1143	CTCCATGTCTG	ATAG

22 / 36

1144	CTTGGACAGG	ATCT
1145	TGCTGTTGTA	CAGG
1146	GTGCTGTTGT	ACAG
1147	TTGGCGTAGT	AGTC
1148	TCCACCATT	GCAC
1149	GATTTTCGTTG	TGGG
1150	GTCATAGATT	TCGTTGTG
1151	TGTACTCTGC	TTGAAC
1152	GTGTACTCTG	CTTG
1153	TGCTGTGTGT	ACTC
1154	CTGATGTGTT	GAAGAACA
1155	CTCTGATGTG	TTGAAG
1156	GCTCTGATGT	GTTG
1157	GAGCTCTGAT	GTGT
1158	CACTTTTAAC	TTGAGCCT
1159	CTCCACTTTT	AACTTGAG
1160	TGCTGTATTT	CTGGTACA
1161	CCAGGAATTG	TTGC
1162	TTGCTGAGGT	ATCG
1163	GATAACCACT	CTGG
1164	CAAAAGATAA	CCACTCTG
1165	CGGTGACATC	AAAAG
1166	CCTCAATTTT	CCCT
1167	GTTATCCCTG	CTGT
1168	GCAGTGTGTT	ATCC
1169	GATGTCCACT	TGCA
1170	TAGTGAACCC	GTTG
1171	TGCCATGAAT	GGTG
1172	GTTCATGCCA	TGAATG
1173	CATGAGAAGC	AGGA
1174	GCTTTGTCAGA	TGCT
1175	GAGCTTTGCA	GATG
1176	TAGTTGGTGT	CCAG
1177	CTGAAGCAAT	AGTTGG
1178	AGCTGAAGCA	ATAGTTGG
1179	GGAGCTGAAG	CAAT
1180	CAATGTACAG	CTGC
1181	GGAAGTCAAT	GTACAG
1182	CGGAAGTCAA	TGTAC
1183	GCGGAAGTCA	ATGT
1184	AGTTGGCATG	GTAG
1185	GCAGAAGTTG	GCAT
1186	CTCCAAATGT	AGGG
1187	ACCTTGCTGT	ACTG
1188	TGCTGGTTGT	ACAG
1189	GGTTATGCTG	GTTG
1190	GTAGTACACG	ATGG
1191	CGTAGTACAC	GATG
1192	CACGTAGTAC	ACGA
1193	CATGTTGGAC	AGCT
1194	GCACGATCAT	GTTG
1195	CACACAGTAG	TGCA
1196	GATCAGAAAA	GCGC

23 / 36

1197	ACCGTGACCA GATG
1198	GTAGACAGGC TGAG
1199	TATCGAGTGT GCTG
1200	TTGCGCATGA ACTG
1201	TTGCTCAGGA TCTG
1202	ACTGGTGAGC TTCA
1203	GCTCAGGATA GTCT
1204	TGTAGATGGA AATCACCT
1205	TGGTGCTGTT GTAG
1206	TTCTCCTGGA GCAA
1207	TACTCTTCGT CGCT
1208	CTTGGCGTAG TACT
1209	CGGCATGTCT ATTTTGTA
1210	CGGGATGGCA TTTT
1211	CTGTAGAAAG TGGG
1212	ACAATTCTGA AGTAGGGT
1213	ATTGCTGAGA CGTCAAAT
1214	TCTCCATTGC TGAG
1215	TCACCAAATT GGAAGCAT
1216	CTCTGAACTC TGCT
1217	AACGAAAGAC TCTGAACT
1218	TGGGTTCTGC AAAC
1219	CTGGCTTTTG GGTT
1220	GTTGTTTCAGG CACT
1221	TCTGATATAG CTCAATCC
1222	TCTTTGGACT TGAGAATC
1223	TGGGTTGGAG ATGT
1224	TGCTGTCGAT GTAG
1225	ACAACCTTTC TGTCGA
1226	ATTGCGCTTC TGCT
1227	GAGGAGAGC CATT
1228	TCAGTTACAT CGAAGG
1229	TGAAGCCATT CATGAACA
1230	TCCTGTCTTT ATGGTG
1231	AAATCCCAGG TTCC
1232	GGACAGTGTA AGCTTATT
1233	GTACAAAAGT GCAGCA
1234	TAGATGGTAC AAAAGTGC
1235	CACTTTATT TGGGATGATG
1236	GCAAATCTTG CTTCTAGT
1237	GTGCCATCAA TACC
1238	GGTATATGTG GAGG
1239	TCTGATCACC ACTG
1240	TCCTAGTGGA CTTTATAG
1241	TTTTTCCTAG TGGACT
1242	CAATAACATT AGCAGG
1243	AAGTCTGTAG GAGG
1244	TCTGTTGTGA CTCAAG
1245	GTTGGTCTGT TGTG
1246	CAAAGCACGC TTCT
1247	TTTCTAAAGC AATAGGCC
1248	GCAATTATCC TGCACA
1249	ACGTAGGCAG CAAT

24 / 36

1250	ATCAATGTAA	AGTGGACG
1251	CTAGATCCCT	CTTG
1252	CCATTTCAC	CCTA
1253	TGGGTTCTG	TATC
1254	TGGCATGTG	CCCT
1255	TCCAGCACAG	AAGT
1256	ATAAATACGG	GCATGC
1257	AGTGTCTGAA	CTCC
1258	TGTGCTGAGT	GTCT
1259	ATAAGCTCAG	GACC
1260	AGGAGAAGCA	GATG
1261	AGCAAGGAGA	AGCA
1262	AATCTTGGGA	CACG
1263	TAGAGAATGG	TTAGAGGT
1264	GTTTTCGCAA	TGTAGTAG
1265	CTTGGGTGTT	TTGC
1266	GCAAGACTTT	ACAATC
1267	GCATTTCGAA	GACTTTAC
1268	TTTAGCTGCA	TTTGCAAG
1269	GCCACTTTTC	CAAG
1270	TTGGTCTTGC	CACT
1271	CAGCACACAG	TAGT
1272	CGATAGTCTT	GCAG

1273	TGF-B2-14/1	25 / 36	CTTTCACCAAATTGGAAG
1274	TGF-B2-14/2		CACCAAATTGGAAGC
1275	TGF-B2-14/3		TCACCAAATTGGAAGC
1276	TGF-B2-15/1		CTCTGGCTTTTGGG
1277	TGF-B2-9/1		CGGCATGTCTATTTTG
1278	relA-1		CACTACAGACGAGC
1279	relA-2		CGTGCACTACAGACG
1280	relA-3		GGAACAGTTCGTCC
1281	relA-4		GAACAGTTCGTCCATG
1282	relA-5		CCAGAGTTTCGGTTC
1283	relA-6		CTAGGACTGGGACAG
1284	relA-7		CGCACTTGTAGCG
1285	relA-8		CTCGCACTTGTAGC
1286	relA-9		GCACTTGTAGC
1287	relA-10		GCGCACTGTCCCTG
1288	relA-11		CCAGGGAGATGCGC
1289	relA-12		GCCGGTGAGGAGG
1290	relA-13		CCGGTGAGGAGGG
1291	relA-14		CGGTTCACTCGGC
1292	relA-15		GAGTTTCGGTTCACTC
1293	relA-16		GGCACGATTGTCAAAG
1294	relA-17		CAGGCGTCACCCCC
1295	relA-18		GCAGGCGTCACCC
1296	p105/p50-1		CTCCCTCCTAAGC
1297	p105/p50-2		CCCTCCTAAGCGG
1298	p105/p50-3		CGAGTCCGCGTTTCG
1299	p105/p50-4		CATCTTCTGCCATTC
1300	p105/p50-5		GTGTTTTCCCAACCAG
1301	p105/p50-6		GGTTTTGGTTCACTAG
1302	p105/p50-7		GCATCTTCACGTCTCC
1303	p105/p50-8		CTTCACGTCTCCTGTC
1304	p105/p50-9		GTCAACCGCGTAGTC
1305	p105/p50-10		CAAATAGGCAAGGTC
1306	p105/p50-11		CTTGCAAATAGGCAAG
1307	p105/p50-12		TGCTTGCAAATAGG
1308	p105/p50-13		CTGCTTGCAAATAGG
1309	p105/p50-14		GCAGGTGGATATTT
1310	p105/p50-15		CTGCTGTTGGCAG
1311	p105/p50-16		CACTAGTTTCCAAGT
1312	p105/p50-17		GTTTTGGTTCACTAG
1313	p105/p50-18		CTTTGATTTCAGGATAG

Fig. 5 - 1

26 / 36

1314	p105/p50-19	GCACTTCTTCTTTATCT
1315	p105/p50-20	CCAAGTCAGATTTCC
1316	p105/p50-21	GTTTCCAAGTCAGATTTTC
1317	p105/p50-22	GGTTCACTAGTTTCC
1318	p105/p50-23	GGTTTTGGTTCACTAG
1319	p105/p50-24	CCGAAAAAATTGGGCA
1320	p105/p50-25	CCGAAAAAATTGGG
1321	p105/p50-26	CTATCCGAAAAAATTGG
1322	p105/p50-27	GTTGATAATGTCATCAG
1323	p105/p50-28	CTCATGTTGATAATGTC
1324	p105/p50-29	CTGTCACCGCGTAG
1325	p105/p50-30	CGTCTCCTGTCACCG
1326	p105/p50-31	CTTCACGTCTCCTG
1327	p105/p50-32	GAGAACTTTATCATGTC
1328	p105/p50-33	GCTATATGCAGGG
1329	p105/p50-34	CCAGCTGCTATATGCAGG
1330	p105/p50-35	AGGCTAAATTTTGCCT
1331	p105/p50-36	GGCTAAATTTTGCC
1332	p105/p50-37	GGCTAAATTTTGCCTTC
1333	p105/p50-38	GCAGGCTAAATTTTGCC
1334	p105/p50-39	GAGTTACCCAAGCG
1335	p105/p50-40	CAGAGTTACCCAAGCG
1336	p105/p50-41	CAGAGTTACCCAAG
1337	p105/p50-42	ACAGAGTTACCCAAG
1338	p105/p50-43	GGTGCAAAACAGAG
1339	p105/p50-44	CTAGGTGCAAAACAG
1340	p105/p50-45	GAGAACTTTATCATGTCC
1341	p105/p50-46	GCTAGATGAATGGC
1342	p105/p50-47	GCAAACATGGCAGGC
1343	p105/p50-48	CAGCAAACATGGCA
1344	p105/p50-49	GCAGCAAACATGGC
1345	p105/p50-50	AGCAGCAAACATGG
1346	p105/p50-51	CAGCAGCAAACATG
1347	p105/p50-52	AGCAGCAGCAAACA
1348	p105/p50-53	CAGCAGCAGCAAACA
1349	p105/p50-54	CAGCAGCAGCAAAC
1350	p105/p50-55	CACCAGCAGCAGCA
1351	p105/p50-56	GCATTGACGTCAGC
1352	p105/p50-57	GATGTTGTCTGTGCTC
1353	p105/p50-58	TGAGATGTTGTCTGTGCT
1354	p105/p50-59	TGAGATGTTGTCTGTG

Fig. 5 - 2

		27 / 36
1355	p105/p50-60	GCCAATGAGATGTTG
1356	p105/p50-61	CTGCCAATGAGATG
1357	p105/p50-62	CACATGGGCATCAC
1358	p105/p50-63	TGTCCACATGGGCA
1359	p105/p50-64	GTACTGTCCACATG
1360	p105/p50-65	CAGCTGCTATATGC
1361	p105/p50-66	GTTCTCCACCAGGG
1362	p105/p50-67	AGTTCTCCACCAGG
1363	p105/p50-68	CAAAGTTCTCCACCAG
1364	p105/p50-69	CCAAGAGTCATCCAGG
1365	p105/p50-70	CCCAAGAGTCATCC
1366	p105/p50-71	CCTGCATTTTCCCAAG
1367	p105/p50-72	TCCTGCATTTTCCC
1368	p105/p50-73	GCCATATCTAGAGGC
1369	p105/p50-74	TCACATCTTCAGCC
1370	p105/p50-75	GCTTCACATCTTCAGC
1371	p105/p50-76	CAGCTTCACATCTTC
1372	p105/p50-77	GTAAC TTATACAGCTGC
1373	p105/p50-78	CCAGTTTTTGTCTGG
1374	p105/p50-79	CCATTTGTCTCAGG
1375	p105/p50-80	GTGTAGCCCATTG
1376	p105/p50-81	GCTTCGGTGTAGCC
1377	p105/p50-82	GATCACTTCAATTGCTTC
1378	p105/p50-83	CTTGTGGAGGCAGG
1379	p105/p50-84	GCTGCCTTGTGGAG
1380	p105/p50-85	CTATTTGCTGCCTTGTGG
1381	p105/p50-86	GGATGTCTCCACGC
1382	p105/p50-87	GGAAGGATGTCTCC
1383	p105/p50-88	TGCGGAAGGATGTC
1384	p105/p50-89	GTTTGCGGAAGGATGTC
1385	p105/p50-90	GCTGAGTTTGCGGA
1386	p105/p50-91	GGTAAAGCTGAGTTTG
1387	p105/p50-92	TCGGTAAAGCTGAG
1388	p105/p50-93	GACTCGGTAAAGCTG
1389	p105/p50-94	AGAGACTCGGTAAAGC
1390	p105/p50-95	GAAATTGTCAGCAGGC
1391	p105/p50-96	GAAATTGTCAGCAGG
1392	p105/p50-97	GGAAATTGTCAGCAGG
1393	p105/p50-98	GGAAATTGTCAGCAG
1394	p105/p50-99	GGGAAATTGTCAGC
1395	p105/p50-100	GTGTGGGAAATTGTC

Fig. 5 - 3

28 / 36

1396	p105/p50-101	GGTTTACACGGTGTG
1397	p105/p50-102	GCITTGGTTTACACG
1398	p105/p50-103	GCACCTTTGGGATGC
1399	NFKB2-1	CCAGGTTCTGCTTCC
1400	NFKB2-2	GCTCTGTCTAGTGGC
1401	NFKB2-3	ACTCTCCATGTCTC
1402	NFKB2-4	CAACTCTCCATGTCTC
1403	NFKB2-5	CAACTCTCCATGTCTC
1404	NFKB2-6	AGCAACTCTCCATG
1405	NFKB2-7	GTAGCAACTCTCCATG
1406	NFKB2-8	GTAGCAACTCTCCA
1407	NFKB2-9	GGTTGTAGCAACTCTCC
1408	NFKB2-10	CGGGCAGTCCTCCA
1409	NFKB2-11	GCACCGGGCAGTC
1410	NFKB2-12	AGGCACCGGGCAG
1411	NFKB2-13	GTGTGTTACCAGGTC
1412	NFKB2-14	TGTGTGTTACCAGGT
1413	NFKB2-15	TGGGTCACTGTGTG
1414	NFKB2-16	CAGACTGTGGGCATG
1415	NFKB2-17	CCCACCAGACTGTGGG
1416	NFKB2-18	CCACCAGACTGTGG
1417	NFKB2-19	TGCCCACCAGACTG
1418	NFKB2-20	CGGCTTCCTCCCC
1419	NFKB2-21	CCTTGTCTTCCACC
1420	NFKB2-22	AACGAGGCTGCCAC
1421	NFKB2-23	GGAAGAAACCGAGG
1422	NFKB2-24	GGGAAGAAACCGAG
1423	NFKB2-25	GGCCATCTGCGCC
1424	NFKB2-26	GCGGCCATCTGCG
1425	NFKB2-27	GTGGCGGCCATCTG
1426	NFKB2-28	ACCGTGGCGGCCAT
1427	NFKB2-29	GCCGCTCAATCTTCATC
1428	NFKB2-30	CTTCATCTTGTGATAGG
1429	NFKB2-31	GCTCAATCTTCATCTTG
1430	NFKB2-32	CAGAAACACTGTTACAG
1431	NFKB2-33	CAGTTGCAGAAACACTG
1432	NFKB2-34	GTTTCAGTTGCAGAAAC
1433	NFKB2-35	CTTCCACCAGAGGG
1434	NFKB2-36	GTCTTCCACCAGAG
1435	NFKB2-37	CTTGTCTTCCACCAGAG
1436	NFKB2-38	TCCTTGTCTTCCAC

Fig. 5 - 4

29 / 36

1437	NFKB2-39	CTTCCTTGTCTTCCAC
1438	NFKB2-40	CATCTTGTGATAGGG
1439	NFKB2-41	GCTAGGTGCAGTGGT
1440	NFKB2-42	GATGGCTAGGTGCA
1441	NFKB2-43	GTGGATGATGGCTAG
1442	NFKB2-44	CCCGTGGATGATGG
1443	NFKB2-45	CTGCCCCGTGGATGA
1444	NFKB2-46	AGAGCCTCCACCCA
1445	NFKB2-47	GTTGTACTCTCGAGC
1446	NFKB2-48	CGTTGTACTCTCG
1447	NFKB2-49	CGCGTTGTACTCTC
1448	NFKB2-50	GAGTCTCCATGCCG
1449	NFKB2-51	CTGAGTCTCCATGC
1450	NFKB2-52	CATGGCTGAGTCTC
1451	NFKB2-53	TGCATGGCTGAGTC
1452	NFKB2-54	GCGTTCACGTTGGC
1453	NFKB2-55	GTGCGAGCGTTCAC
1454	NFKB2-56	AGGTGCGAGCGTTC
1455	NFKB2-57	GCAAAGGTGCGAGC
1456	NFKB2-58	CCTGGTGGCTCAGG
1457	NFKB2-59	GTCAGTCACCTGAG
1458	NFKB2-60	CAGGTCAGTCACCTG
1459	NFKB2-61	CAGCAGGTCAGTCAC
1460	NFKB2-62	GCAGCAGGTCAGTC
1461	NFKB2-63	CATTTAGCAGCAAGGTC
1462	NFKB2-64	GCAGCATTTAGCAGC
1463	NFKB2-65	CTGAGCAGCATTTAG
1464	NFKB2-66	CCCATGAGAATCCT
1465	NFKB2-67	CCTTCCCATGAGAATCC
1466	NFKB2-68	TCCTCCCCCTTCCCA
1467	NFKB2-69	GCCTCCAGTAGACC
1468	NFKB2-70	GTCAGACAGGGCCT
1469	NFKB2-71	CCATGTCAGACAGG
1470	NFKB2-72	GGCCCATGTCAGAC
1471	TANK-1	GCTATTCCTGAAATCAC
1472	TANK-2	CCTCTTGTCTTCTTACC
1473	TANK-3	GGAGAAGAAACCTCTTG
1474	TANK-4	CCTTGCTGAAGTTTCTT
1475	TANK-5	CCAAGACTCCTTGC
1476	TANK-6	CCCTTTCATGGAGC
1477	TANK-7	CCTCTTGGTGTGAC

30 / 36

1478	TANK-8	GACTAAGGATGCCG
1479	TANK-9	GTGGCAGGACTAAGG
1480	TANK-10	AGACGTGGCAGGAC
1481	I-kappa-Bepsilon-1	CTTCCAGCAGGCAG
1482	I-kappa-Bepsilon-2	GTTCTCTGCCTGG
1483	I-kappa-Bepsilon-3	GATGTTCTCTGCCTG
1484	I-kappa-Bepsilon-4	GAGATGTTCTCTGCC
1485	I-kappa-Bepsilon-5	GTGAGATGTTCTCTG
1486	I-kappa-Bepsilon-6	CAGAGAGTGAGATGTTCC
1487	I-kappa-Bepsilon-7	CCAGAGAGTGAGATGTTT
1488	I-kappa-Bepsilon-8	GGTCCAGAGAGTGAG
1489	I-kappa-Bepsilon-9	GAGGTCCAGAGAGTG
1490	I-kappa-Bepsilon-10	GGTCTGTAGTGCC
1491	TRAF-6-1	GATTTTATGATGCAGGC
1492	TRAF-6-2	GACCTGCATCCCTTATTG
1493	TRAF-6-3	TAGTTGATTTTCCAGCAG
1494	TRAF-6-4	GAATCTCACGTTTGC
1495	TRAF-6-5	CAGAGAAAGAATCTCACG
1496	TRAF-6-6	TTTCAACATCAGAGAAAG
1497	TRAF-6-7	CATTTGGACATTTACC
1498	TRAF-6-8	CCTTCATTTGGACATTTT
1499	TRAF-6-9	CAATGTGCTTGATGATCC
1500	Rank-1	CGCATCGGATTTCTC
1501	Rank-2	CAAACCGCATCGGATTTT
1502	Rank-3	GAAGTGCAAACCGC
1503	Rank-4	GCAGAGAAGAACTGC
1504	Rank-5	GCAAGTAAACATGGG
1505	Rank-6	GGTCCACGTTTGG
1506	Rank-7	GCAAGGGTCCACGTTT
1507	Rank-8	TGGCTTCTTCTTCAGGG
1508	Rank-9	TCCTGCTGGCTTCTTC
1509	Rank-10	GTCTGCTGGCTTC
1510	IL-5-1	GGTAGTCTAGGAATTGG
1511	IL-5-2	CTTGCAGGTAGTCTAGG
1512	IL-5-3	GAAACTCTTGCAGGTAG
1513	IL-5-4	CACCAAGAACTCTTGC
1514	IL-5-5	CATTACACCAAGAACTC
1515	IL-5-6	CTCGGTGTTTATTACACC
1516	IL-5-7	CTTTCTATTATCCACTCG
1517	IL-5-8	CCAGTTTAGTCTCAACTT
1518	IL-5-9	AACCAGTTTAGTCTCAAC

Fig. 5 - 6

1519	IL-5-10	ACAAACCAGTTTAGTCTC
1520	IL-13-1	CTCGCGAAAAAGTTTCTT
1521	IL-13-2	CCCTCGCGAAAAAGTTTC
1522	IL-13-3	GTCCCTCGCGAAAAAG
1523	IL-13-4	CAGTTGAACCGTCCC
1524	IL-13-5	GCTTTCGAAGTTTCAGTT
1525	IL-13-6	GATGCTTTCGAAGTTTC
1526	IL-13-7	CTGTCTCTGCAAATAATG
1527	IL-15-1	CACTTATTACATTACCCC
1528	IL-15-2	TTTTCCTCCAGTTCCTC
1529	IL-15-3	GGACAATATGTACAAAACCTC
1530	IL-15-4	GTTGATGAACATTTGGAC
1531	IL-15-5	GTGTTGATGAACATTTGG
1532	I-kappaB(newmember)-1	CAAAATTTGGCCAGGG
1533	I-kappaB(newmember)-2	GCCCCAAAATTTGGCC
1534	I-kappaB(newmember)-3	CCCAGCCCCAAAATTTGG
1535	I-kappaB(newmember)-4	GTCCCCAGCCCCAAAATT
1536	I-kappaB(newmember)-5	AAATCGCCAGAGGCTG
1537	I-kappaB(newmember)-6	ACCAAATCGCCAGAGG
1538	I-kappaB(newmember)-7	CATCACCAAATCGCCAG
1539	Prostaglan.Rec.EP3-1	TAGGAGTGGTTGAGGC
1540	Prostaglan.Rec.EP3-2	GTGTAGGAGTGGTTGAG
1541	Prostaglan.Rec.EP3-3	CTGTGTAGGAGTGG
1542	Prostaglan.Rec.EP3-4	CCCACATGCCTGTG
1543	Prostaglan.Rec.EP3-5	CGATGAACAACGAG
1544	Prostaglan.Rec.EP3-6	CTGGCGATGAACAACG
1545	Prostaglan.Rec.EP3-7	CGCTGGCGATGAAC
1546	Prostaglan.Rec.EP3-8	GAGCTAGTCCCGTTG
1547	Prostaglan.Rec.EP3-9	GCGAAGAGCTAGTCC
1548	Prostaglan.Rec.EP3-10	CCAGTTATGCGAAGAGC
1549	Prostaglan.Rec.EP3-11	CCCCAGTTATGCGAAG
1550	PresenilinI-1	CACATGCTTGCGC
1551	PresenilinI-2	GATCACATGCTTGCGC
1552	PresenilinI-3	GACAAAGAGCATGATCAC
1553	PresenilinI-4	GAGTCACAGGGACAAAG
1554	PresenilinI-5	GAGAGTCACAGGGAC
1555	PresenilinI-6	GCAGAGAGTCACAGG
1556	PresenilinI-7	CCATGCAGAGAGTC
1557	PresenilinI-8	CCACCATGCAGAGAG
1558	PresenilinI-9	TAGCCACGACCACC
1559	PresenilinI-10	GATTAGCTGCCCATCCTT

1560	PresenilinI-11	GGTATAGATTAGCTGCC
1561	PresenilinI-12	GTATCTTCTGTGAATGGG
1562	PresenilinI-13	CTGGCCCCACAGTCT
1563	PresenilinI-14	CTCTGGCCCCACAGT
1564	PresenilinI-15	TGCAGGGCTCTCTG
1565	PresenilinI-16	AGTGCAGGGCTCTC
1566	PresenilinI-17	CACTGATCATGATGGC
1567	PresenilinI-18	GACACTGATCATGATGGC
1568	PresenilinI-19	ACAATGACACTGATCATG
1569	PresenilinI-20	GAACCACCAGGAGGAT
1570	PresenilinI-21	GACACAAAACAGCCACT
1571	PresenilinI-22	GTGGACCTTTCGGAC
1572	PresenilinI-23	CAACCAGCATACGAAGT
1573	PresenilinI-24	TCCCTCTGGGCTTC
1574	PresenilinI-25	ACTGTCCCTCTGGG
1575	PresenilinI-26	GACTGTCCCTCTGG
1576	PresenilinI-27	CCTAGATGACTGTCCC
1577	PresenilinI-28	CAGCGAGGATACTGC
1578	PresenilinI-29	CTTCACCAGCGAGGAT
1579	PresenilinI-30	TTTCCTCTGGGTCTTCAC
1580	PresenilinI-31	CTTTCCTCTGGGTCTTC
1581	PresenilinI-32	CTCCCAATCCAAGTTTT
1582	TRADD-1	TTCATCCCGGAGCC
1583	TRADD-2	TTCTTCATCCCGGAGC
1584	TRADD-3	GCTCAGCCAGTTCTTC
1585	TRADD-4	GACAGAGAGGGCAC
1586	TRADD-5	CTTCACCTCCGACAG
1587	TRADD-6	GAAAAGTCTGGGCAGG
1588	TRADD-7	GACCCTGGAACAGAAAAG
1589	TRADD-8	CTGACCCTGGAACAG
1590	TRADD-9	ACTACAGGCTGACCCT
1591	TRADD-10	ATTCACTACAGGCTGACC
1592	TRADD-11	CGATTCACTACAGG
1593	TRADD-12	GGCCGATTCACTAC
1594	TRADD-13	CGAACGTCTGTTGGTC
1595	TRADD-14	CGCGAACGTCTGTTG
1596	PKA-1	CTTCTGTTTGTGCGAGGAT
1597	PKA-2	TTCACCACCTTCTGTTTG
1598	PKA-3	AGGATGCGCTTTTCATTC
1599	PKA-4	AGCTTGCGAGGATGCG
1600	PKA-5	GTTGACAGCTTGCGAGGAT

1601	PKA-6	GGAACGGAAAGTTGACAG
1602	PKA-7	AACTCGAGTTTGACGAGG
1603	PKA-8	TGTCCITGAAGGAGAAC
1604	PKA-9	CGTACTCCATGACCATGT
1605	PKA-10	GCACGTACTCCATGAC
1606	PKA-11	GATTCTCCGGCTTCAG
1607	PKA-12	TCAATGAGCAGATTCTCC
1608	PKA-13	GGTCAATGAGCAGATTTC
1609	PKA-14	CCCTGCTGGTCAATG
1610	PKA-15	TAGCCCTGCTGGTC
1611	PKA-16	CGCTTGGCGAAACC
1612	PKA-17	CCTTCACGCGCTTG
1613	PKA-18	AAGGTCCAAGTGCG
1614	PKA-19	TGCCGCACAAGGTC
1615	IL-12alpha-1	GGTGAGGACCACCATTT
1616	IL-12alpha-2	GGGTGTCACAGGTG
1617	IL-12alpha-3	ATACCATCTTCTTCAGGG
1618	IL-12alpha-4	GGTGATAACCATCTTCTTC
1619	IL-12alpha-5	CCAGGTGATAACCATCTTC
1620	IL-12alpha-6	CCTCACTGCTCTGGT
1621	IL-12alpha-7	TAAGACCTCACTGC
1622	IL-12alpha-8	CAGAGCCTAAGACCTC
1623	IL-12alpha-9	CCAGAGCCTAAGACC
1624	IL-12alpha-10	TCCTCCTTTTTGTGAAGC
1625	IL-12alpha-11	GACCAAATTCATCTTCC
1626	IL-12alpha-12	ATCAGTGGACCAAATTCC
1627	IL-12alpha-13	GGTTCTTTCTGGTCCTTT
1628	IL-12alpha-14	TTTTTGGGTTCTTTCTGG
1629	IL-12alpha-15	GGTCTTATTTTGGGTTT
1630	IL-12alpha-16	AATGGGCAGACTCTCCT
1631	IL-12alpha-17	TCCACCATGACCTCAATG
1632	IL-12alpha-18	AACGGCATCCACCATG
1633	IL-12alpha-19	GTGAACGGCATCCAC
1634	IL-12alpha-20	ACTTGAGCTTGTGAACGG
1635	IL-12alpha-21	TTCACTTGAGCTTGTG
1636	IL-12alpha-22	CTGGTGTAGTTTTCATAC
1637	IL-12alpha-23	AGCTGCTGGTGTAGTTTT
1638	IL-12beta-1	AGGAGGACCAGGGT
1639	IL-12beta-2	AGGTGGTCCAGGAG
1640	IL-12beta-3	TTTCTGGCCAACTGAGG
1641	IL-12beta-4	GGAGGTTTCTGGCC

1642	IL-12beta-5	TCTGGAGTGGCCAC
1643	IL-12beta-6	CTTCTGGAGCATGTTGCT
1644	IL-12beta-7	GCCTTCTGGAGCATG
1645	IL-12beta-8	GTTTGTCTGGCCTTCTG
1646	IL-12beta-9	GAGTTTGTCTGGCCTTCT
1647	IL-12beta-10	CTAGAGTTTGTCTGGCCT
1648	IL-12beta-11	GCAAGGGTAAAATTCTAG
1649	IL-12beta-12	AGTGCAAGGGTAAAATTCT
1650	IL-12beta-13	AAACAGGCCTCCACT
1651	IL-12beta-14	CTTGGTTAATTCCAATGG
1652	IL-12beta-15	AGGCAACTCCCATTAGTT
1653	IL-12beta-16	TACTACTAAGGCACAGGG
1654	IL-12beta-17	AATACTACTAAGGCACAG
1655	IL-12beta-18	GTACATCTTCAAGTCTTC
1656	Pg-R	GGAGTGGACATGAT
1657	thr	AAGAAGATGAAGCCTTTG
1658	ref-fosjun	CCGTCTTACTCTTCTTGG
1659	PIV	CCGATACAATTCCAAGG
1660	PIV	CCTTTCCCTTCTGAG
1661	PIV	CTGTTGCAAGTACG
1662	bak	CAGAAGCAGAGGGC
1663	bak	CCTCAGAAGCAGAGG
1664	bak	CTCCTCAGAAGCAG
1665	bak	ACAGGCTGGTGGCA
1666	bak	CCACTCTCAACAGGC
1667	bak	ACGGTAGCCGAAGC
1668	bak	GACGGTAGCCGAAGC
1669	bak	GGCCAGACGGTAGC
1670	bak	GTGTAGGGCCAGACGGTA
1671	bak	CCGAAGCCATTTTTCAGG
1672	bak	CCCCGAAGCCATTTTTC
1673	bak	GGTTGATGTCGTCC
1674	bax	GCTTGAGACACTCGC
1675	bax	CCGGACCCGTCCAT
1676	bclx	GCTTGCTTTACTGC
1677	bclx	GGTTGCTCTGAGAC
1678	bclx	GCCACAGTCATGCC
1679	bmp	CGGGCATGCTGGCG
1680	bmp	GTGAAGTTCAGGATGATC
1681	bmp	CCAGTGCCTCATGG
1682	ICE	CAGTGTTCTCCATGG

35 / 36

1683	ICE	CTGTACCAGACCGAG
1684	ICE	GCATACTGTTTCAGC
1685	ich	GCCATCAGCTCCTTG
1686	ich	CCACACCATAGATGG
1687	ich	GCTGGAGCAGTTTCC
1688	bcl1	CTCGCTTCTGCTGC
1689	bcl2	ACCGTGGCAAAGCG
1690	mucrep	AGGTGACACCGTGG
1691	AHR	GACTTGATTCCCTTCAG
1692	AHR	GGATTTGACTTGATTCC
1693	AHR	GCTGCTGTTTCATGG
1694	AHR	CCGTTTCTTTCACTAGG
1695	CD2	CTTGAAGTAGGAGC
1696	MEK2	CGCTCCTACATGGC
1697	tnf	GATGAGGTACAGGCC
1698	tnf	GTAGATGAGGTACAG
1699	tnf	GAGTAGATGAGGTAC
1700	tnf	CCTGGGAGTAGATG
1701	tnf	GGACCTGGGAGTAG
1702	tnf	ACATGGGTGGAGGG
1703	tnf	GTGCTCATGGTGTC
1704	tnf	CTTTCAGTGCTCATG
1705	tnf	TGCTTTCACTGCTCA
1706	tnf	GATGATCTGACTGCC
1707	tnf	GTTCGAGAAGATGATC
1708	tnf	GGGTTTCGAGAAGATG
1709	tnf	GGTTTGCTACAACATG
1710	tnf	CAGCTTGAGGGTTTG
1711	tnf	TGCCCCCTCAGCTTG
1712	TNFR	GACACACACTATCTC
1713	IL-18	GCAGCCATCTTTATTC
1714	IL-18	GTTTCAGCAGCCATC
1715	IL-18	TGGTTCAGCAGCCA
1716	IL-18	CTACTGGTTCAGCAGC
1717	IL-18	TCTACTGGTTCAGC
1718	IL-18	GCCACAAAGTTGATGC
1719	IL-18	CATTGCCACAAAGTTG
1720	IL-18	GAGAACTTGGTCATTC
1721	IL-18	GGTCAATGAAGAGAAC
1722	IL-18	CGATTTCCCTGGTC
1723	IL-18	CCGATTTCCCTGGTC

1724	IL-18	CAAATAGAGGCCGATTTC
1725	IL-18	CAAATAGAGGCCGA
1726	IL-18	CCTCTAGGCTGGCT
1727	IL-18	CATACCTCTAGGCTG
1728	IL-18	AGCCATACCTCTAG
1729	IL-18	CAGCCATACCTCTAG
1730	IL-18	CACAGAGATAGTTACAG
1731	IL-18	GTCTTCGTTTTGAACAG
1732	IL-18	CTAGTCTTCGTTTTGAAC
1733	IL-18	TAGCTAGTCTTCGTTTTG
1734	IL-18	GAGCCACTGCGCC
1735	IL-18	CGTGAGCCACTGCG
1736	IL-12-Rec	CGTAACGATCACTGG
1737	IL-12-Rec	GCACTCGTAACGATC
1738	IL-12-Rec	GGAGCACTCGTAAC
1739	IL-12-Rec	CATCATCCTGAGGT
1740	IL-12-Rec	CAGTATCATCATCCTG
1741	IL-12-Rec	CTCAGTATCATCATCC
1742	IL-12-Rec beta2	CTAAAAGTATGTGCCATC
1743	IL-12-Rec beta2	CACATCGCCTCTCT
1744	IL-12-Rec beta2	GCTTCACAGTCACATCGC
1745	IL-12-Rec beta2	GGAAGGCTTCACAGTC
1746	IL-12-Rec beta2	CCTGTGACTTGAGAATTG
1747	IL-12-Rec beta2	GGAAGACCTGTGAC
1748	IL-12-Rec beta2	CTCTGCTCCACATATTTG
1749	IL-12-Rec beta2	CAACGAAGATCTCTG
1750	IL-12-Rec beta2	CAACACCAACGAAG
1751	PKC-beta	GGTCTTCTGTTTGC
1752	CB-1-Rec	CGATGAAGTGGTAGGAAG
1753	TGF-alpha	GGTTGCATGGAAGC
1754	Fascin	GGTCACAAACTTGCC
1755	p300	CTGATTTGGTCCACTAG
1756	CBP	CATGTTAGCACTGTTC
1757	rac-alpha	GGTCTTGATGTACTCC
1758	EBV	CCACCTAAAGAGAGATC
1759	HSPQ	CTTGTA CTGCACCATC
1760	CC-CKR1	GCCAGTTAAGAAGATG
1761	CC-CKR4	GAGATCATGATCCATGG
1762	c-CRK	GTAGTGTCCCAATAGTG
1763	c-CRK	CTTCCTCATCATTCCC
1764	CRKL	CACAAGCTTTTCGAC

Fig. 5 - 12